Tetrahydroisoquinoline compounds as KEAP1 binding agents
Novel bifunctional compounds targeting the KEAP1 E3 ligase complex expand the scope of protein degradation, addressing limitations in existing PROTAC technologies by effectively recruiting a variety of proteins for therapeutic intervention.
Patent Information
- Application Number
- JP2024524648
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-25
- Filing Date
- 2022-10-25
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current PROTAC technologies are limited by the lack of effective ligase recruiting groups for a broader range of E3 ligases, particularly KEAP1, which restricts the scope of targetable proteins for degradation.
Development of novel bifunctional compounds that recruit target proteins to the KEAP1 E3 ligase complex for degradation, utilizing specific KEAP1 ligand recruitment groups.
Enables the targeted degradation of a wider range of proteins, including Bromodomain and Extraterminal (BET) family proteins, androgen receptor, estrogen receptors, BCL-XL, IRAK4, STAT3, BTK, and TRK, through selective KEAP1 binding, enhancing therapeutic potential.
Smart Images

Figure 2024542974000001 
Figure 2024542974000002 
Figure 2024542974000003
Abstract
Description
[Technical field]
[0001] The present invention relates to tetrahydroisoquinoline compounds that are KEAP1 binding agents and their incorporation into bifunctional compounds that can act as protein degradation inducers. The present invention also relates to methods for the preparation of these bifunctional compounds and their use in the treatment of diseases or disorders associated with proteins that can be degraded via KEAP1 E3 ligase. [Background technology]
[0002] PROTAC® (Proteolysis-inducing Chimeric Molecules) are proteolysis-inducing compounds that consist of an E3 ligase recruiter, a ligand that targets a protein of interest (POI), and a linker that attaches these two functional groups to each other. Through E3 ligase binding to the E3 ligase recruiter, PROTAC® can promote ubiquitination of the POI, leading to proteasomal degradation of the POI. Of the approximately 600 predicted human family E3 ligases, only a small number of E3 ligase recruiters have been identified to date, with the four most widely used being thalidomide-based immunomodulators that recruit cereblon (CRBN), hydroxyproline ligands that target von Hippel-Lindau (VHL) E3 ligase, nutlins that recruit MDM2, and ligands that target cIAP. The lack of broader E3 ligase targeting capability limits the range of POIs that can be degraded, and therefore there is a need to identify effective ligase recruitment groups for a broader range of E3 ligases. Kelch-like ECH-binding protein 1 (KEAP1) is a Bric-a-Brac (BTB) Kelch protein that functions as a substrate adaptor protein for the Cullin3 (CUL3) / Ring-Box1 (RBX1)-dependent E3 ubiquitin ligase complex (doi:10.1128 / MCB.24.16.7130-7139.2004) with its best-known substrate, the nuclear transcription factor Nrf2. The KEAP1-CUL3 E3 ligase complex binds Nrf2 via its N-terminal Neh2 domain and promotes 26S ubiquitin proteasomal degradation. KEAP1 has also been shown to be involved in the degradation of other substrates, such as IKKb (doi:10.1016 / j.molcel.2009.07.025), and it is therefore anticipated that other POIs can be targeted for degradation via recruitment of KEAP1 and its associated complexes using suitable KEAP1-binding motifs attached to ligands that selectively bind to those POIs.Such an approach has been recently validated for BET family bromodomain POIs using a known KEAP1 ligand, bardoxolone (doi:10.1038 / s41598-020-72491-9), and a second ligand, KI-696, which binds to the BET inhibitor JQ-1 (doi:10.1021 / jacs.1c04841). WO2020 / 018788 describes benzotriazole degradation inducers that target proteins via KEAP1 ligase. WO2020 / 210229 describes bifunctional molecules that degrade KEAP1 (i.e., KEAP1 is the POI). The scope of KEAP1 E3 ligase-based PROTACs® has been recently explored (doi:10.1016 / j.chembiol.2022.08.003).
[0003] Thus, there is a need to identify bifunctional protein degradation inducers (PROTACs®) that have selective KEAP1 ligand recruitment groups. Summary of the Invention
[0004] In one aspect, the present invention provides novel bifunctional compounds that function to recruit target proteins to the KEAP1 E3 ligase complex for degradation.
[0005] In one aspect, the present invention provides a compound of formula I, as defined herein, or a pharma- ceutically acceptable salt thereof.
[0006] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula I, as defined herein, or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable excipients.
[0007] In another aspect, the present invention relates to a compound of formula I as defined herein, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in therapy.
[0008] In another aspect, the present invention relates to a method for treating a disease or disorder resulting from the degradation of a protein of interest, said method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I as defined herein, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined herein.
[0009] The present invention further provides a process for the synthesis of a compound of formula I as defined herein, or a pharma- ceutically acceptable salt thereof.
[0010] In another aspect, the present invention provides a compound of formula I or a pharma- ceutically acceptable salt thereof, obtainable or obtained or directly obtained by a synthetic process as defined herein.
[0011] Preferred, preferred and optional features of any one of the particular aspects of the invention are also preferred, preferred and optional features of any other aspect. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] definition Unless otherwise stated, the following terms used in the specification and claims have the meanings set forth below.
[0013] References to "treat" or "treatment" should be understood to include prevention as well as alleviation of established symptoms of a condition. Thus, "treat" or "treatment" of a condition, disorder or condition includes (1) preventing the appearance or slowing the progression of clinical symptoms of a condition, disorder or condition that develop in a person who may be affected by or predisposed to the condition, disorder or condition, but who has not yet experienced or exhibited clinical or subclinical symptoms of the condition, disorder or condition, (2) inhibiting the condition, disorder or condition, i.e., arresting, reducing or slowing the progression of the disease, or its recurrence (in the case of maintenance therapy), or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, i.e., diminishing the condition, disorder or condition, or at least one clinical or subclinical symptom thereof.
[0014] "Therapeutically effective amount" means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc., of the mammal being treated.
[0015] As used herein, the term "KBG" refers to the KEAP1 binding group.
[0016] As used herein, the term "PBG" means protein binding group.
[0017] In this specification, the term "alkyl" includes both straight-chain and branched-chain alkyl groups. References to individual alkyl groups such as "propyl" are specific for the straight-chain version only, and references to individual branched-chain alkyl groups such as "isopropyl" are specific for the branched-chain version only. For example, "(1-6C)alkyl" includes (1-4C)alkyl, (1-3C)alkyl, propyl, isopropyl, and t-butyl. The same rule applies to other groups, for example, "phenyl(1-6C)alkyl" includes phenyl(1-4C)alkyl, benzyl, 1-phenylethyl, and 2-phenylethyl.
[0018] As used herein, the term "alkylene" includes straight and branched chain divalent alkyl groups. For example, "C 1-4 "Alkylene" includes methylene (-CH2-), ethylene (-CH2CH2-), propylene, and butylene.
[0019] As used herein, the term "alkoxy" includes straight and branched chain alkyl groups attached to an oxygen atom through a single bond. For example, 1-4 "Alkoxy" includes methoxy, ethoxy, isopropoxy and t-butoxy.
[0020] The term “(m-nC)” or “(m-nC) group” used alone or as a prefix, refers to any group having m through n carbon atoms.
[0021] "Cycloalkyl" means a hydrocarbon monocyclic or bicyclic ring containing carbon atoms. Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Bicyclic rings may be joined by fused or spiro-fused connections, and examples of bicyclic cycloalkyl groups include bicyclo[2.2.2]octane, bicyclo[2.1.1]hexane, bicyclo[1.1.1]pentane, spiro[2.4]heptane, bicyclo[4.1.0]heptane, and bicyclo[2.2.1]heptane.
[0022] The term "halo" refers to fluoro, chloro, bromo, and iodo.
[0023] The term "haloalkyl" is used herein to refer to each alkyl group in which one or more hydrogen atoms are replaced by halogen (e.g., fluorine) atoms. Examples of haloalkyl groups include fluoroalkyl groups such as -CHF2, -CH2CF3, or perfluoroalkyl / alkoxy groups such as -CF3 or -CF2CF3.
[0024] The term "heterocyclyl", "heterocyclic" or "heterocycle" refers to a non-aromatic saturated or partially saturated monocyclic, fused, bridged or spiro-fused bicyclic heterocyclic ring system(s). Monocyclic heterocycles contain about 3-12 (suitably 3-7) ring atoms with 1-5 (suitably 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur in the ring. Bicyclic heterocycles contain 7-17 ring atoms, suitably 7-12 ring atoms in the ring. The bicyclic heterocycle(s) may be fused, spiro-fused or bridged ring systems. Examples of heterocyclic groups include cyclic ethers such as oxiranyl, oxetanyl, tetrahydrofuranyl, dioxanyl and substituted cyclic ethers. Nitrogen-containing heterocycles include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrotriazinyl, tetrahydropyrazolyl, etc. Exemplary sulfur-containing heterocycles include tetrahydrothienyl, dihydro-1,3-dithiol, tetrahydro-2H-thiopyran, and hexahydrothiepin. Other heterocycles include dihydro-oxathiolyl, dihydroisoxazolyl (e.g. 4,5-dihydroisoxazolyl), dihydropyridinyl (e.g. 1,2-dihydropyridinyl or 1,6-dihydropyridinyl), tetrahydro-oxazolyl, tetrahydro-oxadiazolyl, tetrahydro-dioxazolyl, tetrahydro-oxathiazolyl, hexahydrotriazinyl, tetrahydro-oxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. Sulfur-containing heterocycles also include sulfur-oxidized heterocycles containing SO or SO groups. Examples include sulfoxide and sulfone forms of tetrahydrothienyl and thiomorpholinyl, such as tetrahydrothienyl 1,1-dioxide and thiomorpholinyl 1,1-dioxide.Suitable values for heterocyclyl groups having one or two oxo (=O) or thioxo (=S) substituents are, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl. Particular heterocyclyl groups are 3-7 membered saturated monocyclic heterocyclyls containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur, such as azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, tetrahydrothienyl, tetrahydrothienyl 1,1-dioxide, thiomorpholinyl, thiomorpholinyl 1,1-dioxide, piperidinyl, homopiperidinyl, piperazinyl or homopiperazinyl. As will be appreciated by those skilled in the art, any heterocycle may be linked to another group through any suitable atom, such as through a carbon or nitrogen atom. Suitably, the term "heterocyclyl", "heterocyclic" or "heterocycle" will refer to a 4-, 5-, 6- or 7-membered monocyclic ring as described above.
[0025] The term "heteroaryl" or "heteroaromatic" refers to a monocyclic, bicyclic, or polycyclic aromatic ring incorporating one or more (e.g., 1 to 4, particularly 1, 2, or 3) heteroatoms selected from nitrogen, oxygen, or sulfur. Examples of heteroaryl groups are monocyclic and bicyclic groups containing 5 to 12 ring members, more typically 5 to 10 ring members. Heteroaryl groups can be, for example, 5- or 6-membered monocyclic rings or 9- or 10-membered bicyclic rings, such as fused 5- and 6-membered rings, or bicyclic structures formed from two fused 6-membered rings. Each ring may contain up to about 4 heteroatoms, typically selected from nitrogen, sulfur, and oxygen. Typically, heteroaryl rings will contain up to 3 heteroatoms, more typically up to 2, e.g., 1 heteroatom. In one embodiment, a heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atom in the heteroaryl ring can be basic, as in the case of imidazole or pyridine, or essentially non-basic, as in the case of indole or pyrrole nitrogen.Generally, the number of basic nitrogen atoms present in the heteroaryl group will be less than 5, including any amino substituents on the ring.Appropriately, the term "heteroaryl" or "heteroaromatic" refers to a 5- or 6-membered monocyclic heteroaryl ring, as described above.
[0026] Non-limiting examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinol ... Examples of such aryl groups include xalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3-b]furanyl, 2H-furo[3,2-b]-pyranyl, 5H-pyrido[2,3-d]-o-oxazinyl, 1H-pyrazolo[4,3-d]-oxazolyl, 4H-imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl, imidazo[2,1-b]thiazolyl, and imidazo[1,2-b][1,2,4]triazinyl. "Heteroaryl" also encompasses partially aromatic bicyclic or polycyclic systems in which at least one ring is aromatic and one or more of the other ring(s) is non-aromatic, saturated or partially saturated, provided that at least one ring contains one or more heteroatoms selected from nitrogen, oxygen or sulfur.Examples of partially aromatic heteroaryl groups include, for example, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo-1,2,3,4-tetrahydroquinolinyl, dihydrobenzthienyl, dihydrobenzfuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, 2,2-dioxo-1,3-dihydro-2-benzothienyl, 4,5,6,7-tetrahydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydro-1,8-naphthalidinyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl, 4,5 ,6,7-tetrahydrobenzo[d]isoxazolyl, 4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridinyl, 5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazinyl, 5,6-dihydro-4H-pyrrolo[1,2-c][1,2,3]triazolyl, 6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazolyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridinyl, 6,7-dihydro-4H-[1,2,3]triazolo[5,1-c][1,4]-oxazinyl and 1,4,5,6-tetrahydrocyclopenta[d][1,2,3]triazol-5-yl.
[0027] Non-limiting examples of 5-membered heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, and tetrazolyl groups.
[0028] Non-limiting examples of 6-membered heteroaryl groups include, but are not limited to, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, and triazinyl.
[0029] Specific non-limiting examples of bicyclic heteroaryl groups containing a 6-membered ring fused to a 5-membered ring include, but are not limited to, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolinyl, isoindolinyl, purinyl (e.g., adeninyl, guaninyl), indazolyl, benzodioxolyl, pyrrolopyridine, and pyrazolopyridinyl groups.
[0030] Specific non-limiting examples of bicyclic heteroaryl groups containing two fused 6-membered rings include, but are not limited to, quinolinyl, isoquinolinyl, chromanyl, thiochromanyl, chromenyl, isochromenyl, chromanyl, isochromanyl, benzodioxanyl, quinolidinyl, benzoxazinyl, benzodiazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, and pteridinyl groups.
[0031] Specific non-limiting examples of bicyclic heteroaryl groups containing a 5-membered ring fused to a 5-membered ring include, but are not limited to, 6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazolyl and 1,4,5,6-tetrahydrocyclopenta[d][1,2,3]triazol-5-yl.
[0032] The term "aryl" refers to a cyclic or polycyclic aromatic ring having 5 to 12 carbon atoms. The term "aryl" includes both monovalent and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, and the like. In this particular embodiment, the aryl is phenyl or naphthyl, particularly phenyl.
[0033] The term "carboxylic acid mimetic group" refers to an alternative structure or equivalent of a carboxylic acid group, which generally maintains the characteristics of the carboxylic acid group required for biological activity, but the physicochemical properties of the resulting compound, such as acidity or lipophilicity, are altered. Such carboxylic acid mimetic groups are known to those skilled in the art of medicinal chemistry. Examples of carboxylic acid mimetic groups include, but are not limited to, tetrazole, 3-trifluoromethyl-1,2,4-triazole, hydroxamic acid, hydroxamic acid ester, phosphonic acid, phosphinic acid, sulfonic acid, sulfinic acid, sulfonamide, sulfonylurea, acylurea, thiazolidinedione, oxazolidinedione, oxadiazol-5(4H)-one, thiadiazol-5(4H)-one, oxathiadiazole-2-oxide, oxadiazol-5(4H)-thione, isoxazole, tetramic acid, cyclopentane-1,3-dione, and cyclopentane-1,2-dione.
[0034] The term "optionally substituted" refers to either groups, structures, or molecules that are substituted and to either groups, structures, or molecules that are not substituted.
[0035] When optional substituents are selected from "one or more" groups, this definition should be understood to include all substituents selected from one of the specified groups, or substituents selected from two or more of the specified groups.
[0036] The phrase "compounds of the invention" refers to the compounds disclosed herein both generically and specifically.
[0037] Compounds of the Invention In a first aspect, the present invention provides a compound of formula I: [ka] or a pharma- ceutically acceptable salt thereof, wherein L is a divalent linking group covalently linking KBG to PBG; PBG is a protein binding group that contains a moiety that has binding affinity for a target protein of interest; KBG has the structure shown below: [ka] is a KEAP1 binding group having the formula During the ceremony, R 1 is C 1-4 Alkylene-R 11 , heterocyclyl, and 8-10 membered bicyclic heteroaryl, wherein the heterocyclyl is independently selected from C 1-4 Alkyl, -C(O)-R 12 , SO2-R 13 , C 1-3 Alkylene-OR 14 and, independently, C. 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH, C 1-3 Optionally substituted by one or more substituents selected from heteroaryl, optionally substituted by one or more substituents selected from alkoxy and cyano; the 8-10 membered bicyclic heteroaryl is independently selected from C 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH and C 1-3 optionally substituted with one or more substituents selected from alkoxy; R 2 is hydrogen, fluoro, chloro and C 1-3 alkyl; R 3 is hydrogen, fluoro, chloro, bromo, C 1-3 Alkoxy, C 1-3 Alkyl, C 1-3 selected from haloalkyl and cyano; R 4 is hydrogen or C 1-4 is alkyl, R 5 -C(O)-C 1-4 alkyl, -C(O)-heteroaryl or -C(O)-aryl, wherein the heteroaryl and aryl are C 1-4 Alkyl, halo, hydroxy, C1-3 Alkoxy, CO2R 15 and cyano; or R 4 and R 5 together with the nitrogen atom to which they are attached form a 4-, 5- or 6-membered heterocyclyl ring, said heterocyclyl ring being contains one or more -C(O)- moieties attached to a nitrogen atom; optionally fused to an aryl or heteroaryl ring; C 3-7 optionally spiro-attached to a cycloalkyl group; Independently C 1-4 Alkyl, halo, OH, C 1-3 Alkoxy, C 1-3 Haloalkyl, Cyano, NR 16 R 17 , C(O)R 18 , S(O)R 19 and SO2R 20 optionally substituted with one or more substituents selected from; L 1 and L 2 is a bond and -CR 21 R 22 - independently selected; R 6 and R 7 are independently hydrogen, C 1-4 Alkyl and C 3-7 cycloalkyl; or R 6 and R 7 together with the carbon atoms to which they are attached form a 3-, 4-, 5- or 6-membered cycloalkyl ring; R 8 is C(=O)NR 8a R 8b , -C(=O)R 8c , CO2R 23 , C(O)NHSO2C 1-3alkyl, tetrazolyl, 3-trifluoromethyl-1,2,4-triazol-5-yl, and carboxylic acid analogs selected from hydroxamic acid, hydroxamic acid ester, phosphonic acid, phosphinic acid, sulfonic acid, sulfinic acid, sulfonamide, sulfonylurea, acylurea, thiazolidinedione, oxazolidinedione, oxadiazol-5(4H)-one, thiadiazol-5(4H)-one, oxathiadiazole-2-oxide, oxadiazole-5(4H)thione, isoxazole, tetramic acid, cyclopentane-1,3-dione, and cyclopentane-1,2-dione; R 8a is hydrogen or C 1-6 is alkyl, R 8b is hydrogen, C 1-6 Alkyl or C 3-7 Cycloalkyl, C 1-6 Alkyl group or C 3-7 Cycloalkyl groups are C 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH, C 1-3 Alkoxy, C 1-3 Haloalkyl, Cyano, NR 16 R 17 , C(O)R 18 , S(O)R 19 and SO2R 20 or R 8a and R 8b together with the nitrogen atom to which they are attached form a 3-, 4-, 5-, 6- or 7-membered heterocyclyl ring, the heterocyclyl ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulfur; 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH, C 1-3 Alkoxy, C 1-3 Haloalkyl, Cyano, NR 16 R 17 , C(O)R 18 , S(O)R 19 and SO2R 20optionally substituted with one or more substituents independently selected from R 8c is C 1-3 Alkyl or C 1-3 is haloalkyl; R 9 is hydrogen, C 1-4 Alkyl, Hydroxy, C 1-3 selected from alkoxy and halo; R 10 is hydrogen and C 1-4 alkyl; or R 9 and R 10 together with the carbon atom to which they are attached form a 3-, 4-, 5- or 6-membered cycloalkyl ring; or L 2 is a bond, and R 7 and R 10 together with the atoms to which they are attached form a 4-, 5-, 6- or 7-membered cycloalkyl or heterocyclyl ring; The heterocyclyl ring contains 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; The cycloalkyl ring optionally contains one or two carbon-carbon double bonds, and further contains a C 1-3 Optionally bridged by an alkylene group, or R 9 Optionally, a carbon atom in the ring may have a C * C to concatenate 1-3 is an alkylene group; The cycloalkyl and heterocyclyl rings are 1-4 Alkyl, halo, OH, C 1-3 Alkoxy, C 1-3 optionally substituted with one or more substituents independently selected from haloalkyl and deuterium; R 11 is -C(O)-R 24 , -SO2-R 25 , -NR 26 C(O)-R 27 , -NR 28 SO2-R 29, heterocyclyl, aryl and heteroaryl, wherein the heterocyclyl, aryl and heteroaryl groups are selected from 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 Optionally substituted with one or more substituents independently selected from alkoxy, heterocyclyl and cyano; the heterocyclyl group is 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy, oxo, and cyano; R 12 is C 1-4 Alkyl, C 3-7 Cycloalkyl, OR 31 , N.R. 32 R 33 , aryl and heteroaryl, wherein the aryl and heteroaryl are selected from C 1-4 Alkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; R 13 is C 1-4 Alkyl, C 3-7 Cycloalkyl, heteroaryl, heterocyclyl and NR 34 R 35 wherein the heteroaryl and heterocyclyl are selected from 1-4 Alkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; R 17 is hydrogen, C 1-4 Alkyl, C(O)C 1-3 Alkyl and C(O)NR 36 R 37 Selected from; R 18 , R19 and R 20 is C 1-4 Alkyl, OH, C 1-3 Alkoxy and NR 38 R 39 are independently selected from; R 23 is hydrogen and C 1-4 alkyl; R 24 is C 1-4 Alkyl, NR 40 R 41 and OR 42 Selected from; R 25 is C 1-4 Alkyl and NR 43 R 44 Selected from; R 27 is C 1-4 Alkyl, C 3-7 Cycloalkyl, C 1-3 haloalkyl, heterocyclyl, aryl and heteroaryl, wherein the aryl and heteroaryl are selected from 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 45 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; R 29 is C 1-4 Alkyl, C 3-7 Cycloalkyl, C 1-3 haloalkyl, aryl and heteroaryl, wherein the aryl and heteroaryl are selected from C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 46 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; R 30 is hydroxy, C 1-3 Alkoxy, C 3-7Cycloalkyl, cyano and NR 47 R 48 Selected from; R 40 is hydrogen and C 1-4 alkyl; R 41 is hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl, C 1-3 selected from alkoxy, aryl and heteroaryl; or R 40 and R 41 together with the nitrogen atom to which they are attached form a 4-, 5- or 6-membered heteroaryl or heterocyclyl ring, the heteroaryl and heterocyclyl rings being C 1-4 Alkyl, halo, OH, C 1-3 Alkoxy, C 3-7 optionally substituted with one or more substituents independently selected from cycloalkyl and cyano; R 45 and R 46 is hydroxy, C 1-3 Alkoxy and C 3-7 cycloalkyl; R 14 , R 15 , R 16 , R 21 , R 22 , R 26 , R 28 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 42 , R 43 , R 44 , R 47 and R 48 is hydrogen, C 1-4 Alkyl and C 3-7 cycloalkyl.
[0038] Particular compounds of the invention include, for example, compounds of formula I, or a pharma- ceutically acceptable salt thereof, unless otherwise specified, 1 , R 2 , R 3 , R 4 , R 5 , L 1 , L 2 , R 6 , R 7 , R 8 , R 8a , R 8b , R 8c , R 9 , R 10 , R 11 , R 12 , R 13 , R 17 , R 18 , R 19 , R 20 , R 24 , R 25 , R 27 , R 29 , R 30 , R 40 , R 41 Each of , L or PBG has any of the meanings defined above or in any of the following paragraphs (1) to (126). For the avoidance of doubt, the present invention encompasses any combination of two or more of the definitions set out in paragraphs (1) to (126): (1)R 1 is C 1-4 Alkylene-R 11 is; (2)R 1 is CH2-R 11 is; (3)R 1 is CH2CH2-R 11 is; (4)R 1 is CH(Me)-R 11 is; (5)R 1 is heterocyclyl, C 1-4 Alkyl, -C(O)-R 12 , SO2-R 13 , heteroaryl and C 1-3 Alkylene-OR 14and the heteroaryl is optionally substituted with one or more substituents independently selected from 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; (6)R 1 is heterocyclyl, C 1-4 Alkyl, -C(O)-R 12 , SO2-R 13 , heteroaryl and C 1-3 Alkylene-OR 14 and the heteroaryl is optionally substituted with one or more substituents independently selected from 1-4 Alkyl and C 3-7 optionally substituted with one or more substituents independently selected from cycloalkyl; (7)R 1 is piperidinyl or pyrrolidinyl, respectively, -C(O)-R 12 , SO2-R 13 , heteroaryl and C 1-3 Alkylene-OR 14 and the heteroaryl is optionally substituted with one or more substituents independently selected from 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; (8)R 1 is pyrrolidinyl, -C(O)-R 12 , SO2-R 13 , heteroaryl and C 1-3 Alkylene-OR 14 and the heteroaryl is optionally substituted with one or more substituents independently selected from 1-4 Alkyl or C 3-7 cycloalkyl optionally substituted; (9)R 1 is the following group: [ka] is selected from one of [ka] indicates the point of attachment of this group to an oxygen atom in the rest of the compound, and each group is represented by -C(O)-R 12 , SO2-R 13 , heteroaryl and C 1-3 Alkylene-OR 14 and the heteroaryl is optionally substituted with one or more substituents independently selected from 1-4 Alkyl or C 3-7 cycloalkyl optionally substituted; (10)R 1 is C 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH and C 1-3 is an 8-10 membered bicyclic heteroaryl optionally substituted with one or more substituents independently selected from alkoxy; (11)R 1 is C 1-4 Alkyl, OH and C 1-3 is an 8-membered bicyclic heteroaryl optionally substituted with one or more substituents independently selected from alkoxy; (12)R 1 is the following group: [ka] [ka] , is selected from one of [ka] indicates the point of attachment of this group to an oxygen atom in the rest of the compound, and each cyclic group is 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy, heterocycloalkyl, and cyano; (13)R 2 is selected from hydrogen, fluoro and chloro; (14)R 2 is hydrogen or fluoro; (15)R 3 is hydrogen, chloro, bromo, C 1-3 Alkoxy, C 1-3 Alkyl, C 1-3 selected from haloalkyl and cyano; (17)R 3 is selected from hydrogen, chloro, bromo, methoxy, methyl, trifluoromethyl and cyano; (18)R 3 is selected from hydrogen and chloro; (19)R 3 is chloro; (20)R 4 is hydrogen; (21)R 5 is -C(O)-C 1-4 alkyl or -C(O)-aryl, the aryl group being C 1-4 Alkyl, halo, hydroxy, C 1-3 Alkoxy, CO2R 15 and cyano; (22)R 4 is hydrogen, and R 5 is -C(O)-C1-4 alkyl or -C(O)-aryl, the aryl group being C 1-4 Alkyl, halo, hydroxy, C 1-3 Alkoxy, CO2R 15 and cyano; (23)R 4 is hydrogen, and R 5 is -C(O)-C 1-4 alkyl or -C(O)-aryl, the aryl group being selected from halo, hydroxy, and COR. 15 optionally substituted with one or more substituents selected from; (24)R 4 and R 5 together with the nitrogen atom to which they are attached form a 4-, 5- or 6-membered heterocyclyl ring, said heterocyclyl ring containing one or more -C(O)- moieties attached to the nitrogen atom and optionally fused to an aryl ring, or C 3-7 Optionally spiro-attached to the cycloalkyl group; said heterocyclyl ring is 1-4 Alkyl, halo, OH, C 1-3 Alkoxy, C 1-3 Haloalkyl, Cyano, NR 16 R 17 , C(O)R 18 , S(O)R 19 and SO2R 20 optionally substituted with one or more substituents independently selected from (25)R 4 and R 5 together with the nitrogen atom to which they are attached form a 5-membered heterocyclyl ring, said heterocyclyl ring containing a -C(O)- moiety attached to the nitrogen atom and optionally fused to an aryl ring, or C 3-7 Optionally spiro-attached to the cycloalkyl group; said heterocyclyl ring is 1-4 Alkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; (26)R 4 and R 5together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclyl ring, said heterocyclyl ring containing a -C(O)- moiety attached to the nitrogen atom and optionally fused to an aryl ring, or C 3-7 Optionally spiro-attached to the cycloalkyl group; said heterocyclyl ring is 1-4 optionally substituted with one or more substituents independently selected from alkyl, halo, OH; (27)R 4 and R 5 together with the nitrogen atom to which they are attached form a 5-membered heterocyclyl ring, said heterocyclyl ring containing a -C(O)- moiety attached to the nitrogen atom and optionally fused to a phenyl ring or optionally spiro-linked to a cyclopropyl group; said heterocyclyl ring is optionally substituted with one or more substituents independently selected from methyl, fluoro and OH; (28)R 4 and R 5 together with the nitrogen atom to which they are attached, form: [ka] and the saturated ring of the heterocyclic moiety is selected from one of 3-7 Optionally spiro-linked to the cycloalkyl group, said heterocyclic moiety being 1-4 optionally substituted with one or more substituents independently selected from alkyl, halo, and OH; (29)R 4 and R 5 together with the nitrogen atom to which they are attached, form: [ka] wherein the saturated ring of the heterocyclic moiety is optionally spiro-linked to a cyclopropyl group, said heterocyclic moiety being optionally substituted with one or more substituents independently selected from methyl, fluoro and OH; (30)R 4 and R 5together with the nitrogen atom to which they are attached form the following heterocyclic moiety: [ka] wherein the heterocyclic moiety is optionally spiro-linked to the cyclopropyl group or is optionally substituted with one or more substituents independently selected from methyl and fluoro; (31)R 4 and R 5 together with the nitrogen atom to which they are attached form the following heterocyclic moiety: [ka] wherein the heterocyclic moiety is optionally spiro-linked to the cyclopropyl group and further comprises C 1-3 The alkyl is optionally substituted with the cyclopropyl and / or 1-3 The alkyl group is attached to the heterocycle at the α or β position relative to the carbonyl group; (32)R 4 and R 5 together with the nitrogen atom to which they are attached to form the moiety: [ka] form; (33)L 1 and L 2 is independently selected from a bond and -CH2-; (34)L 1 is a bond, and L 2 is -CH2-; (35)L 1 is CH2-, and L 2 is a bond; (36)L 1 and L 2 are both bonds; (37)R 6 and R 7 is hydrogen and C 1-4 independently selected from alkyl; (38)R 6 and R 7is independently selected from hydrogen and methyl; (39)R 6 and R 7 are both hydrogen; (40)R 6 and R 7 together with the carbon atoms to which they are attached form a 3-, 4-, 5- or 6-membered cycloalkyl ring; (41)R 8 is C(=O)NR 8a R 8b , -C(=O) R8c , CO2R 23 , C(O)NHSO2C 1-3 selected from alkyl, tetrazolyl and 3-trifluoromethyl-1,2,4-triazol-5-yl; (42)R 8 is C(=O)NR 8a R 8b , -C(=O)R 8c , COH and tetrazolyl; (43)R 8 is C(=O)NR 8a R 8b and CO2H; (44)R 8 is CO2H; (45)R 8 is C(=O)NR 8a R 8b is; (46)R 8 is -C(=O)R 8c is; (47)R 8a is hydrogen or methyl; (48)R 8a is hydrogen; (49)R 8b is hydrogen, C 1-6 Alkyl or C 3-7 Cycloalkyl, C 1-6 Alkyl groups include halo, OH, C 1-3 Alkoxy, C 3-7 Cycloalkyl, cyano, NR 16 R 17 , C(O)R 18, S(O)R 19 and SO2R 20 optionally substituted with one or more substituents independently selected from (50)R 8b is hydrogen, C 1-4 Alkyl or C 3-5 Cycloalkyl, C 1-4 Alkyl groups include halo, OH, C 1-3 Alkoxy, C 3-7 optionally substituted with one or more substituents independently selected from cycloalkyl and cyano; (51)R 8b is C 1-4 Alkyl or C 3-5 Cycloalkyl, C 1-4 The alkyl groups are fluoro, OH, C 1-3 Alkoxy, C 3-7 optionally substituted with one or more substituents independently selected from cycloalkyl and cyano; (52)R 8b is hydrogen, methyl, ethyl, n-propyl, cyclopropyl, cyclobutyl, or cyclopropylmethyl, wherein the methyl, ethyl, or n-propyl group is optionally substituted with one or more substituents independently selected from fluoro, OH, methoxy, and cyano; (53)R 8b is methyl, ethyl, n-propyl, cyclopropyl, cyclobutyl or cyclopropylmethyl; (54)R 8b is methyl; (55)R 8a is hydrogen, and R 8b is hydrogen, C 1-6 Alkyl or C 3-7 Cycloalkyl, C 1-6 Alkyl groups include halo, OH, C 1-3 Alkoxy, C 3-7 Cycloalkyl, cyano, NR 16 R 17 , C(O)R 18 , S(O)R 19 and S.O. 2 R 20optionally substituted with one or more substituents independently selected from (56)R 8a is hydrogen, and R 8b is C 1-6 Alkyl or C 3-7 Cycloalkyl, C 1-6 The alkyl groups are fluoro, OH, C 1-3 Alkoxy, C 3-7 Cycloalkyl, cyano, NR 16 R 17 , C(O)R 18 , S(O)R 19 and S.O. 2 R 20 optionally substituted with one or more substituents independently selected from (57)R 8a is hydrogen, and R 8b is methyl, ethyl, n-propyl, cyclopropyl, cyclobutyl or cyclopropylmethyl; (58)R 8a is hydrogen, and R 8b is methyl; (59)R 8a and R 8b together with the nitrogen atom to which they are attached form a 3-, 4- or 5-membered heterocyclyl ring, the heterocyclyl ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulfur, and further comprising C 1-4 Alkyl, halo, OH, C 1-3 Alkoxy, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, cyano, NR 16 R 17 , C(O)R 18 , S(O)R 19 and SO2R 20 optionally substituted with one or more substituents independently selected from (60)R 8a and R 8b together with the nitrogen atom to which they are attached form a 4- or 5-membered heterocyclyl ring, the heterocyclyl ring being 1-4 Alkyl, halo, OH, C 1-3 Alkoxy, C1-3 Haloalkyl, C 3-7 Cycloalkyl, cyano, NR 16 R 17 , C(O)R 18 , S(O)R 19 and SO2R 20 optionally substituted with one or more substituents independently selected from (61)R 8a and R 8b together with the nitrogen atom to which they are attached, they are methyl, fluoro, OH, methoxy and C 1-3 forming an azetidinyl ring optionally substituted with one or more substituents independently selected from fluoroalkyl; (62)R 8c is C 1-3 Alkyl or C 1-3 is fluoroalkyl; (63)R 8c is C 1-3 is fluoroalkyl; (64)R 8c is fluoromethyl, difluoromethyl or trifluoromethyl; (65)R 9 is hydrogen, C 1-4 Alkyl, C 1-3 selected from alkoxy and halo; (66)R 9 is selected from hydrogen, methyl, methoxy and fluoro; (67)R 9 is C 1-4 Alkyl, C 1-3 selected from alkoxy and halo; (68)R 9 is selected from methyl, methoxy and fluoro; (69)R 9 is hydrogen or C 1-4 is alkyl, (70)R 9 is hydrogen or methyl; (71)R 9 is methyl; (72)R 10 is selected from hydrogen and methyl; (73)R 9 and R 10 together with the carbon atom to which they are attached form a 3-, 4-, 5- or 6-membered cycloalkyl ring; (74)L 2 is a bond, and R 7 and R 10 together with the atoms to which they are attached form a 4-, 5- or 6-membered cycloalkyl or heterocyclyl ring; The heterocyclyl ring contains 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; The cycloalkyl ring optionally contains one or two carbon-carbon double bonds and optionally a C linking two carbon atoms of the ring. 1-3 Bridged by an alkylene group, or R 9 Optionally, a carbon atom in the ring may have a C * C to concatenate 1-3 is an alkylene group; The cycloalkyl and heterocyclyl rings are 1-4 Alkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy, and deuterium; (75)L 1 and L 2 are both bonds, and R 7 and R 10 together with the atoms to which they are attached form a 4-, 5- or 6-membered cycloalkyl or heterocyclyl ring; The heterocyclyl ring contains 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; The cycloalkyl ring optionally contains a carbon-carbon double bond and optionally a C 1-3 Bridged by an alkylene group, or R 9 Optionally, a carbon atom in the ring may have a C * C to concatenate 1-3 is an alkylene group; The cycloalkyl and heterocyclyl rings are 1-4Alkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy, and deuterium; (76)L 2 is a bond, and R 7 and R 10 together with the atoms to which they are attached form a 4-, 5- or 6-membered cycloalkyl ring, said cycloalkyl ring having a C linking two carbon atoms of the ring. 1-3 Optionally bridged by an alkylene group, or R 9 may optionally have a C atom in the ring. * C to concatenate 1-3 is an alkylene group, and the cycloalkyl ring is 1-4 Alkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and deuterium; (77)L 2 is a bond, and R 7 and R 10 together with the atoms to which they are attached form a cyclohexyl ring, said cyclohexyl ring optionally containing a carbon-carbon double bond and further a C linking two carbon atoms of the ring. 1-3 Optionally bridged by an alkylene group, or R 9 may optionally have a C atom in the ring. * C to concatenate 1-3 is an alkylene group, and the cyclohexyl ring is 1-4 optionally substituted with one or more substituents independently selected from alkyl, halo, OH, and deuterium; (78)R 11 is -C(O)-R 24 , -NR 26 C(O)-R 27 , heterocyclyl and heteroaryl, the heterocyclyl and heteroaryl groups being selected from 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3optionally substituted with one or more substituents independently selected from alkoxy, heterocyclyl, and cyano; (79)R 11 -C(O)-R 24 and R 24 is NR 40 R 41 and OR 42 Selected from; (80)R 11 Ha-NR 26 C(O)-R 27 and R 27 is C 1-4 Alkyl, C 3-7 cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the aryl and heteroaryl are selected from C 1-4 Alkyl and C 3-7 optionally substituted with one or more substituents independently selected from cycloalkyl; (81)R 11 is C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 heteroaryl optionally substituted with one or more substituents independently selected from alkoxy, heterocyclyl, and cyano; (82)R 11 is C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , C 1-3 heteroaryl optionally substituted with one or more substituents independently selected from alkoxy, and cyano; (83)R 11 is methyl, ethyl, isopropyl, difluoromethyl, trifluoromethyl, chloro, fluoro, cyclopropyl, methoxy, cyano, oxetanyl, CH2-R 30 and CH2CH2-R 30is heteroaryl optionally substituted with one or more substituents independently selected from (84)R 11 is pyridyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, 1,2,3-triazolyl, 1,2,4-oxadiazolyl, benzotriazolyl, benzisoxazolyl, isoxazolopyridinyl, imidazopyridinyl or triazolopyridinyl, respectively, C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy, heterocyclyl, and cyano; (85)R 11 teeth, [ka] Selected from C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy, heterocycloalkyl, and cyano; (86)R 11 is oxazolyl, isoxazolyl or 1,2,3-triazolyl, each of which is C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy, heterocycloalkyl, and cyano; (87)R 11 is C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R30 , Halo, OH, C 1-3 1,2,3-triazolyl optionally substituted with one or more substituents independently selected from alkoxy, heterocycloalkyl, and cyano; (88)R 11 is C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 heterocyclyl optionally substituted by one or more substituents independently selected from alkoxy, oxo, and cyano; (89)R 11 is C 1-4 Alkyl, C 1-3 heterocyclyl optionally substituted by one or more substituents independently selected from haloalkyl, halo, OH, and oxo; (90)R 29 is C 1-4 Alkyl, C 3-7 Cycloalkyl, C 1-3 haloalkyl and heteroaryl, wherein the heteroaryl is selected from C 1-4 Alkyl and C 1-3 Optionally substituted with one or more substituents independently selected from haloalkyl (91)R 29 is methyl, ethyl or cyclopropyl; (92)R 30 is hydroxy, C 1-3 Alkoxy, C 3-7 selected from cycloalkyl and cyano; (93)R 30 is selected from hydroxy, methoxy, cyclopropyl and cyano; (94)R 40 is selected from hydrogen and methyl; (95)R 41 is selected from hydrogen, methyl, cyclopropyl, methoxy and phenyl; (96)R 40 and R 41together with the nitrogen atom to which they are attached form a 5-membered heteroaryl or heterocyclyl ring, said heteroaryl and heterocyclyl rings being C 1-4 Alkyl, halo, OH, C 1-3 Alkoxy, C 3-7 optionally substituted with one or more substituents independently selected from cycloalkyl and cyano; (97)R 40 and R 41 together with the nitrogen atom to which they are attached form a 5-membered heterocyclyl ring, said heterocyclyl ring being 1-4 optionally substituted with one or more substituents independently selected from alkyl, halo, and OH; (98)R 40 and R 41 together with the nitrogen atom to which they are attached form a 5-membered heterocyclyl ring, said heterocyclyl ring being optionally substituted with one or more substituents independently selected from methyl, fluoro and OH; (99) L is a covalent bond or a divalent, saturated or unsaturated, linear or branched hydrocarbon chain containing 1 to 50 carbon atoms; 0 to 6 alkylene units of L are independently -Cy-, -O-, -N(R), -S-, -OC(O)-, -C(O)O-, -S(O)-, -S(O)2-, -N(R)S(O)2-, -S(O)2N(R)-, -N(R)C(O)-, -C(O)N(R)-, -OC(O)N(R)-, [ka] Replaced by; Each -Cy- is i) phenylenyl, ii) 8-10 membered bicyclic arylenyl, iii) 4- to 7-membered saturated or partially unsaturated carbocyclenyl; iv) 4- to 7-membered saturated or partially unsaturated spiro carbocyclenyl; v) 8-10 membered bicyclic, saturated or partially unsaturated carbocyclylenyl, vi) 4- to 7-membered saturated or partially unsaturated heterocyclylenyl having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; vii) 4- to 7-membered saturated or partially unsaturated spiro heterocyclylenyl having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; viii) 8-10 membered bicyclic, saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, sulfur or oxygen; ix) 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; and x) an independently optionally substituted divalent ring selected from 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each n is independently 1 to 10; Each R is independently hydrogen or C 1-6 optionally substituted with a group selected from alkyl, phenyl, a 4- to 7-membered saturated or partially unsaturated heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5- to 6-membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; (100) L is a divalent, saturated or unsaturated, linear or branched hydrocarbon chain containing 1 to 20 carbon atoms; 0 to 6 alkylene units of L are independently -Cy-, -O-, -N(R), -S-, -OC(O)-, -C(O)O-, -S(O)-, -S(O)2-, -N(R)S(O)2-, -S(O)2N(R)-, -N(R)C(O)-, -C(O)N(R)-, -OC(O)N(R)-, [ka] Replaced by; Each -Cy- is i) phenylenyl, ii) 8-10 membered bicyclic arylenyl, iii) 4- to 7-membered saturated or partially unsaturated carbocyclenyl; iv) 4- to 7-membered saturated or partially unsaturated spiro carbocyclenyl; v) 8-10 membered bicyclic, saturated or partially unsaturated carbocyclylenyl, vi) 4- to 7-membered saturated or partially unsaturated heterocyclylenyl having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; vii) 4- to 7-membered saturated or partially unsaturated spiro heterocyclylenyl having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; viii) 8-10 membered bicyclic, saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, sulfur or oxygen; ix) 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; and x) an independently optionally substituted divalent ring selected from 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each n is independently 1 to 10; Each R is independently hydrogen or C 1-6optionally substituted with a group selected from alkyl, phenyl, a 4- to 7-membered saturated or partially unsaturated heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5- to 6-membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; (101) L is a divalent, saturated or unsaturated, linear or branched hydrocarbon chain containing 1 to 20 carbon atoms; 0 to 6 alkylene units of L are independently selected from -O-, -N(R), -S-, -OC(O)-, -C(O)O-, -S(O)-, -S(O)2-, -N(R)S(O)2-, -S(O)2N(R)-, -N(R)C(O)-, -C(O)N(R)-, -OC(O)N(R)-, 4 to 7 membered saturated or partially unsaturated heterocyclylenyl having 1 to 2 heteroatoms independently selected from nitrogen, oxygen and sulfur; [ka] Replaced by; Each n is independently 1 to 10; each R is independently hydrogen or C 1-6 is alkyl; (102) L is a divalent, saturated linear hydrocarbon chain containing 5 to 15 carbon atoms; 2 to 6 alkylene units of L are independently -O-, -N(R), -S-, -OC(O)-, -C(O)O-, -S(O)-, -S(O)2-, -N(R)S(O)2-, -S(O)2N(R)-, -N(R)C(O)-, -C(O)N(R)-, -OC(O)N(R)-, 5 to 7 membered saturated heterocyclylenyl having 1 to 2 heteroatoms independently selected from nitrogen, oxygen and sulfur; [ka] Replaced by; Each n is independently 1 to 5; each R is independently hydrogen or C 1-3 is alkyl; (103) L is a divalent, saturated linear hydrocarbon chain containing 1 to 10 carbon atoms; 0 to 4 alkylene units of L are independently -O-, -N(R), -S-, -OC(O)-, -C(O)O-, -S(O)-, -S(O)2-, -N(R)S(O)2-, -S(O)2N(R)-, -N(R)C(O)-, -C(O)N(R)-, -OC(O)N(R)-, 5 to 7 membered saturated heterocyclylenyl having 1 to 2 heteroatoms independently selected from nitrogen, oxygen and sulfur; [ka] Replaced by; Each n is independently 1 to 5; each R is independently hydrogen or C 1-3 is alkyl; (104) L is a divalent, saturated, linear or branched hydrocarbon chain containing 1 to 10 carbon atoms; 0 to 4 alkylene units of L are independently replaced by -O-, -N(R), -S-, -OC(O)-, -C(O)O-, -S(O)-, -S(O)2-, -N(R)S(O)2-, -S(O)2N(R)-, -N(R)C(O)-, -C(O)N(R)-, or -OC(O)N(R); each R is independently hydrogen or C 1-3 is alkyl (e.g., methyl); (105)L is [ka] is selected from the group consisting of * is the point of attachment to KBG or PBG; m is 0 to 4; each p is independently 1 to 4; each R is independently hydrogen or C 1-3 is alkyl (e.g., methyl); (106)L is [ka] is selected from the group consisting of * is the point of attachment to KBG or PBG; m is 0 to 4; each R is independently hydrogen or C 1-3 is alkyl (e.g., methyl); (107)L is -R on KBG 1 group, -N(R 4 )(R 5 ) group, or -L 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )(R 10 ) groups; (108) L is R 8 If not covalently bonded through a substituent, L is -R on KBG. 1 group, -N(R 4 )(R 5 ) group, or -L 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )(R 10 ) groups; (109)L is -R on KBG 1 Covalently bonded to the group; (110)L is -N(R 4 )(R 5 ) group; (111)L is -L on KBG 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )(R 10 ) group; (112) L is R 8 If L is not covalently bonded via a substituent, it is -L on KBG. 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )(R 10 ) group; (113)L is -R on KBG 1 Covalently bonded to the R 1 is a group described in paragraph (12) above; (114)L is -R on KBG 1 Covalently bonded to the R 1 teeth, [ka] is a group selected from [ka] indicates the point of attachment of this group to the oxygen atom of the remaining KBG; each cyclic group is 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy, heterocyclyl, and cyano; (115)L is -R on KBG 1 Covalently bonded to the R 1 is a group described in paragraph (113) or paragraph (114) above; L is a group described in paragraph (114) above; 1 covalently bonded to a heteroaryl or heterocyclyl ring within a group or to a substituent on said heteroaryl or heterocyclyl ring; (116) L is covalently attached to the -R1 group on KBG, where R1 is: [ka] is a group selected from [ka] indicates the point of attachment of this group to the oxygen atom of the remaining KBG; each group is C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy, heterocyclyl, and cyano; * indicates the point of attachment of the linking group L; (117)L is -N(R 4 )(R 5 ) group, replacing either R4 or R5; (118)L is -N(R 4 )(R 5 ) group and is covalently bonded to the -N(R 4 )(R 5 ) is a group described in paragraph (32) above, and L is covalently bonded to any ring atom; (119)L is -N(R 4 )(R 5 ) group and is covalently bonded to the -N(R 4 )(R 5 ) has the following structure: [ka] is selected from one of [ka] indicates the point of attachment of this group to the remainder of KBG; each group is optionally substituted with one or more substituents independently selected from C1-4 alkyl, halo, and OH; * indicates the point of attachment of the linking group L; (120)L is -L on KBG 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )(R 10 ) group, and -L 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )(R 10 ) has the following structure: [ka] is selected from one of [ka] indicates the point of attachment of this group to the rest of the KBG; each group is C 1-4 Alkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and deuterium; * indicates the point of attachment of the linking group L; (121)L is -L on KBG 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )(R 10 ) group, and -L 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )(R 10 ) has the following structure: [ka] is selected from one of [ka] indicates the point of attachment of this group to the remainder of KBG; each group is optionally substituted with one or more substituents independently selected from methyl and fluoro; * indicates the point of attachment of the linking group L; (122)L is -L on KBG 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )(R 10 ) group, and -L 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )(R 10 ) has the following structure: [ka] is selected from one of [ka] indicates the point of attachment of this group to the rest of the KBG; R 8 is selected from COH, C(O)NHSOMe and tetrazolyl; R 9 is hydrogen or methyl; * indicates the point of attachment of the linking group L; (123)L is -L on KBG 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )(R 10 ) group, and -L 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )(R 10 ) has the following structure: [ka] is selected from one of [ka] indicates the point of attachment of this group to the rest of the KBG; R 8 is CO2H; R 9 is methyl; * indicates the point of attachment of the linking group L; (124) PBG is a protein binding group that contains a moiety that has binding affinity to a target protein of interest; the target protein of interest is: (i) Bromodomain and extra-terminal (BET) family proteins (such as BRD3, BRD4, or BRD9); (ii) androgen receptor; (iii) estrogen receptor; (iv) BCL-XL; (v) IRAK4; (vi) STAT3; (vii) BTK; or (viii) is a TRK; (125) PBG is a protein binding group that contains a moiety that has binding affinity to a target protein of interest; the target protein of interest is BRD4; (126) PBG is a protein binding group that includes a moiety that has binding affinity to a target protein of interest, the target protein of interest being BRD4, and the moiety that has binding affinity is [ka] and * indicates the point of attachment of the linking group L.
[0039] Appropriately, R 1 is as defined in any one of paragraphs (1) to (12) above. In one embodiment, R 1 is as defined in paragraph (2) above. In another embodiment, R 1 is as defined in paragraphs (7) to (9) above. In another embodiment, R 1 is defined in paragraph (12) above.
[0040] Appropriately, R 2 is as defined in any one of paragraphs (13)-(14) above. In one embodiment, R 2 is defined in paragraph (14) above.
[0041] Appropriately, R 3 is as defined in any one of paragraphs (15) to (19) above. In another embodiment, R 3 is defined in paragraphs (18)-(19) above.
[0042] Appropriately, R 4 is defined in paragraph (20) above.
[0043] Appropriately, R 5 is defined in paragraph (21) above.
[0044] Appropriately, R 4 and R5 is as defined in any one of paragraphs (22) to (24) above. In another embodiment, R 4 and R 5 is as defined in paragraph (24) above. In one embodiment, R 4 and R 5 is as defined in paragraphs (25) to (32) above. In another embodiment, R 4 and R 5 is as defined in paragraph (29) above. In a further embodiment, R 4 and R 5 is defined in paragraph (32) above.
[0045] Appropriately, L 1 and L 2 is as defined in any one of paragraphs (33) to (36) above. 1 and L 2 is defined in paragraph (36) above.
[0046] Appropriately, R 6 and R 7 is as defined in any one of paragraphs (37) to (40) above.
[0047] Appropriately, R 8 is as defined in any one of paragraphs (41) to (46) above. 8 is as defined in paragraphs (45)-(46) above. In one embodiment, R 8 is defined in paragraph (46) above.
[0048] Appropriately, R 8a is as defined in any one of paragraphs (47)-(48) above. In one embodiment, R 8a has the meaning defined in paragraph (48) above.
[0049] Appropriately, R 8bis as defined in any one of paragraphs (49) to (54) above. 8b is as defined in paragraph (53) or (54) above.
[0050] Appropriately, R 8a and R 8b is as defined in any one of paragraphs (55) to (61) above. In one embodiment, R 8a and R 8b is as defined in paragraph (58) or (61) above.
[0051] Appropriately, R 8c is as defined in any one of paragraphs (62) to (64) above. 8c is defined in paragraph (64) above.
[0052] Appropriately, R 9 is as defined in any one of paragraphs (65) to (71) above. 9 is defined in paragraph (71) above.
[0053] Appropriately, R 10 is defined in paragraph (72) above.
[0054] Appropriately, R 9 and R 10 is defined in paragraph (73) above.
[0055] Appropriately, L 2 , R 7 and R 10 is as defined in any one of paragraphs (74) to (77) above. 2 , R 7 and R 10 is defined in paragraph (77) above.
[0056] Appropriately, R 11is as defined in any one of paragraphs (78) to (89) above. In a further embodiment, R 1 is defined in paragraph (2) above; R 11 is defined in paragraphs (87) to (89) above.
[0057] Appropriately, R 29 is as defined in paragraphs (90)-(91) above. In one embodiment, R 29 is defined in paragraph (91) above.
[0058] Appropriately, R 30 is as defined in paragraphs (92)-(93) above. In one embodiment, R 30 is defined in paragraph (93) above.
[0059] Appropriately, R 40 is defined in paragraph (94) above.
[0060] Appropriately, R 41 has the meaning defined in paragraph (95) above.
[0061] Appropriately, R 40 and R 41 is as defined in any one of paragraphs (96) to (98) above. 40 and R 41 has the meaning defined in paragraph (98) above.
[0062] Suitably, L is as defined in any one of paragraphs (99) to (106) above. In another embodiment, L is as defined in paragraphs (102) to (106) above.
[0063] Suitably, L is covalently linked to KBG as defined in any one of paragraphs (107) to (123) above.
[0064] Suitably, the PBG is as defined in any one of paragraphs (124) to (126) above.
[0065] In one embodiment, KBG has the following structural formulas (II)-(X): [ka] [ka] wherein R 1 ~R 10 , L 1 and L 2 is as defined herein; the cyclohexyl or cyclopentyl ring in formulae (III) to (X) is 1-4 Alkyl, halo, OH, C 1-3 C optionally substituted with one or more substituents independently selected from alkoxy and deuterium, and further comprising a C linking two carbon atoms of the ring 1-3 Optionally bridged by an alkylene group, or R 9 may optionally have a C atom in the ring. * C to concatenate 1-3 is an alkylene group; R 49 and R 50 is hydrogen, C 1-4 independently selected from alkyl and halo; or R 49 and R 50 together with the carbon atom to which they are attached form a cyclopropyl or cyclobutyl ring.
[0066] In one embodiment, KBG has the structural formulas (XI)-(XVI) shown below: [ka] wherein R 1 ~R 3 is as defined herein; R 8 is CO2H or C(O)NR 8a R 8b ;R 51 and R52 is independently selected from hydrogen, methyl, fluoromethyl, and difluoromethyl; R 53 is hydrogen, methyl or C(O)Me.
[0067] In one embodiment, KBG is selected from the group: (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(2-(5-methylisoxazole-3-carboxamido)ethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(2-(benzo[d]oxazole-2-carboxamido)ethoxy)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(5-methylisoxazole-3-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(2-methylthiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-((1-methyl-1H-benzo[d]imidazol-5-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5-bromo-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5-chloro-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5,7-dichloro-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1oxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethoxy)-5-bromo-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5-bromo-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-(((S)-1-(2-methylthiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-bromo-8-(((3S)-1-(5-methyl-5H-114-thiazol-2-yl)pyrrolidin-3-yl)oxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-(((S)-1-(5-methylpyridazin-3-yl)pyrrolidin-3-yl)oxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((4-methyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-methyl-1H-imidazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-methylisoxazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((2-ethyl-2H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-bromo-8-((5-methylthiazol-2-yl)methoxy)-1-((1-oxo-1,3,3a,4,5,6-hexahydro-2H-isoindol-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-1-((1-oxoisoindolin-2-yl)methyl)-8-(pyridazin-3-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-(cyclopropylmethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-(imidazo[1,2-a]pyridin-7-ylmethoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-methyl-1H-benzo[d]imidazol-5-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-(methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-(isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-methyl-1,3,4-oxadiazol-2-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((7-methoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1-((1oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-isopropyl-1H-imidazol-2-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((4-ethyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-cyano-1-ethyl-1H-imidazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-1-((1-oxoisoindolin-2-yl)methyl)-8-((5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-bromo-8-(1-(1-methyl-1H-1,2,3-triazol-4-yl)ethoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-bromo-8-(1-(1-isopropyl-1H-1,2,3-triazol-4-yl)ethoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-bromo-8-(1-(1-isopropyl-1H-1,2,3-triazol-4-yl)ethoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-methylisoxazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethoxy)-5-chloro-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((1-oxoisoindolin-2-yl)methyl)-8-((1-(2,2,2-trifluoroethyl)-1H-imidazol-2-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-(2,2-difluoroethyl)-1H-imidazol-2-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-ethyl-1H-pyrazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-imidazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-fluoro-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methyl-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-cyano-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxy-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-5-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-1-((2-oxopyrrolidin-1-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethoxy)-5-bromo-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-methylthiazol-2-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-isopropyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-bromo-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(benzo[d]isothiazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyridin-2-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-methylisothiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-(isothiazol-3-ylmethoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid (1S,2R)-2-((1S)-5-bromo-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-bromo-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((S)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyridin-3-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-ethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (R)-4-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3-methyl-4-oxobutanoic acid; 1-(((S)-2-((1R,2S)-2-(2H-tetrazol-5-yl)cyclohexane-1-carbonyl)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)pyrrolidin-2-one; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-isopropyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((4-methyl-1H-pyrazol-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyrimidin-5-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclopentane-1-carboxylic acid; (1R,2S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyridazin-3-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((3-methyl-3H-imidazo[4,5-b]pyridin-6-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1,7-dihydroimidazo[1,2-a]pyrimidin-2-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-(isoxazolo[5,4-b]pyridin-3-ylmethoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((3-methylisoxazolo[5,4-b]pyridin-6-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; 3-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)bicyclo[2.2.1]heptane-2-carboxylic acid; 3-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)tetrahydrofuran-2-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-indazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((3-methyl-3H-imidazo[4,5-b]pyridin-5-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; 2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4,4-difluorocyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4,5-dimethyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1R,2S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-fluorocyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((S)-3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((S)-3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((S)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-ethylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-ethylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-ethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-ethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4,5-dimethylisoxazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-chloro-5-methylisoxazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-methylisoxazol-5-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(methoxymethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(2-methoxyethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(cyclopropyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-(((S)-3-methyl-2-oxopyrrolidin-1-yl)methyl)-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-(((R)-3-methyl-2-oxopyrrolidin-1-yl)methyl)-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-8-((1-methyl-5-(trifluoromethyl)-2,3-dihydro-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2S)-2-((S)-5-chloro-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-cyclopropyl-5-(difluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-(difluoromethyl)pyrimidin-5-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5,5-dimethyl-4,5-dihydroisoxazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-methylisoxazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-((4,5,6,7-tetrahydrobenzo[d]isoxazol-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((2,5-bis(difluoromethyl)-2H-1,2,3-triazol-4-yl)methoxy)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; 2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)tetrahydro-2H-pyran-3-carboxylic acid; (R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)bicyclo[2.2.2]octane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid-4,4-d2 acid; (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-(2-methoxyethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5,6-dihydro-4H-pyrrolo[1,2-c][1,2,3]triazol-3-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-2-oxo-1,2-dihydropyridin-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; 1-(((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-2-((1R,2S)-2-methyl-2-(2H-tetrazol-5-yl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)pyrrolidin-2-one; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((4,4-dimethyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-methyl-4-(trifluoromethyl)isoxazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-(difluoromethyl)-5-methylisoxazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(cyclopropyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(methoxymethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(methoxymethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(cyclopropyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-chloro-8-((7-fluoro-2,7a-dihydrobenzo[d]isoxazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((6,7-difluorobenzo[d]isoxazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-methylisoxazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((3-methyl-1,2,4-oxadiazol-5-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2S)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4-(trifluoromethyl)pyrimidin-5-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-cyclopropyl-5-(difluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-(2-(dimethylamino)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-1-methyl-2-((S)-5-methyl-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-methyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-cyclopropyl-5-methyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-fluoro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4,5-dimethyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5,6-dihydro-4H-pyrrolo[1,2-c][1,2,3]triazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-cyclopropyl-4-methyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-imidazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)oxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((6,7-dihydro-4H-[1,2,3]triazolo[5,1-c][1,4]oxazin-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-1-methyl-2-((S)-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-(oxetan-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((1,5-bis(difluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-2-methyl-5-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((S)-2-methyl-5-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((3-oxomorpholino)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2((S)-5-bromo-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(oxetan-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((3-oxomorpholino)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,6R)-6-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohex-3-ene-1-carboxylic acid; 5-(((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-2-((1R,2S)-2-(2,3-dihydro-1l2-tetrazol-5-yl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-5-azaspiro[2.4]heptan-6-one; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)thiazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-methylthiazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1R,3S,4R,6S)-4-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-3-methylbicyclo[4.1.0]heptane-3-carboxylic acid; (1S,3S,4R,6R)-4-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-3-methylbicyclo[4.1.0]heptane-3-carboxylic acid; (1S,2R)-2-((1S)-5-chloro-8-((6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-7-yl)oxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R,4S,5R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid-4,5-d2 acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-6-oxo-1,6-dihydropyridin-2-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-chloro-8-((1-methyl-1,4,5,6-tetrahydrocyclopenta[d][1,2,3]triazol-5-yl)oxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-chloro-8-((1-methyl-1,4,5,6-tetrahydrocyclopenta[d][1,2,3]triazol-5-yl)oxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4,4-difluoro-1-methylcyclohexane-1-carboxylic acid; (1S,2R,4S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4-fluoro-1-methylcyclohexane-1-carboxylic acid; (1S,2R,4R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid-4-d acid; (1S,2R,4S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4-hydroxy-1-methylcyclohexane-1-carboxylic acid; (1S,2R,5S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-5-hydroxy-1-methylcyclohexane-1-carboxylic acid; (1S,2R,5R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-5-hydroxy-1-methylcyclohexane-1-carboxylic acid; (1S,2R,4R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4-hydroxy-1-methylcyclohexane-1-carboxylic acid; (2S,3R)-3-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)tetrahydro-2H-pyran-2-carboxylic acid; (1R,2R,6S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-6-hydroxy-1-methylcyclohexane-1-carboxylic acid; (1R,2R,6R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-6-hydroxy-1-methylcyclohexane-1-carboxylic acid; (1S,2S,3R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-3-hydroxy-1-methylcyclohexane-1-carboxylic acid; (1S,2S,3S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-3-hydroxy-1-methylcyclohexane-1-carboxylic acid; 5-(((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-2-((1R,2S)-2-methyl-2-(1H-tetrazol-5-yl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-5-azaspiro[2.4]heptan-6-one; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((3-oxomorpholino)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4,5-dimethyl-4H-1,2,4-triazol-3-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-7-fluoro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-7-fluoro-8-((5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(4-(methylamino)-4-oxobutoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(ethylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)-5-methylisoxazole-3-carboxamide; (1S,2R)-2-((S)-1-(cyclopropanecarboxamidomethyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-((1H-pyrazol-5-yl)methoxy)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-(acetamidomethyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-N-methyl-2-((S)-1-((2-oxooxazolidin-3-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; 4-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)butanoic acid; (R)-1-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylpiperidine-2-carboxamide; (S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylpyrrolidine-1-carboxamide; 1-(((S)-5-chloro-2-((S)-1-(2,2-difluoroacetyl)piperidine-2-carbonyl)-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)pyrrolidin-2-one; (S)-6((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methyl-5-azaspiro[2.4]heptane-5-carboxamide; (1R,2S)-2-((R)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(4-oxo-4-(pyrrolidin-1-yl)butoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; 5-Cyclopropyl-N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)isoxazole-3-carboxamide; N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)-4,5-dimethylisoxazole-3-carboxamide; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; N-(2-(((S)-2-((1R,2S)-2-(cyclopropylcarbamoyl)cyclohexane-1-carbonyl)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)-5-methylisoxazole-3-carboxamide; N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(3-hydroxyazetidine-1-carbonyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)-5-methylisoxazole-3-carboxamide; N-(2-(((S)-2-((1R,2S)-2-(cyclobutylcarbamoyl)cyclohexane-1-carbonyl)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)-5-methylisoxazole-3-carboxamide; 5-Cyclopropyl-N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)isoxazole-3-carboxamide; N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)benzo[d]oxazole-2-carboxamide; N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)benzo[d]isoxazole-3-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(2-((5-methylisoxazole)-4-sulfonamido)ethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(pyrimidine-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-nicotinoylpyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-((5-methylisoxazol-4-yl)sulfonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)thiazole-2-carboxamide; (1S,2R)-2-((S)-8-(((S)-1-(cyclopropanecarbonyl)pyrrolidin-3-yl)oxy)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(5-methylisoxazole-3-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(oxazol-5-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(2-methylthiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-(((S)-1-(2,4-dimethylthiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(2-methylthiazole-4-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (R)-4-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)-N,3-dimethyl-4oxobutanamide; (1S,2R)-N-methyl-2-((S)-1-((2-oxopyrrolidin-1-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(pyrazin-2-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (S)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylpiperidine-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-propylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(2-methoxyethyl)cyclohexane-1-carboxamide; (1S,2R)-N-(2,2-difluoroethyl)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(2,2,2-trifluoroethyl)cyclohexane-1-carboxamide; (1S,2R)-N-(cyanomethyl)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; (1S,2R)-N-(2,2-difluoro-3-hydroxypropyl)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(2-hydroxyethyl)cyclohexane-1-carboxamide; 1-((S)-1-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)-1-oxopropan-2-yl)-3-methylurea; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5-chloro-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; 5-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-5-oxopentanamide; 4-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-4-oxobutanamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-ethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(3-hydroxypropyl)cyclohexane-1-carboxamide; (1S,2R)-N-methyl-2-((S)-1-(propionamidomethyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-((1-methyl-1H-pyrazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5-bromo-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; Methyl (S)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)pyrrolidine-1-carboxylate; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-ethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-bromo-8-((5-isopropyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-bromo-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-isopropyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (2R,3R)-4-((S)-5-chloro-8-((5-isopropyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N,2,3-trimethyl-4-oxobutanamide; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyridin-3-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyridazin-3-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyrazin-2-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyridin-2-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyrimidin-5-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; 2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclopentane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-(2-(1-methyl-1H-1,2,3-triazol-4-yl)ethoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((3-methyl-3H-imidazo[4,5-b]pyridin-6-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-(isoxazolo[5,4-b]pyridin-3-ylmethoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((3-methylisoxazolo[5,4-b]pyridin-6-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-(imidazo[1,2-a]pyrimidin-2-ylmethoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethoxy)-5-chloro-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(2,2-difluoro-3-hydroxypropyl)cyclohexane-1-carboxamide; (S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylpiperidine-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((3-methyl-3H-imidazo[4,5-b]pyridin-5-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-indazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; 3-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methyltetrahydrofuran-2-carboxamide; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclopentane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((4,5-dimethyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (S)-3-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylmorpholine-4-carboxamide; (S)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylpyrrolidine-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (S)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylpiperidine-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclopentane-1-carboxamide; (1S,2R)-2-((1S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclopentane-1-carboxamide; (1S,2R)-2-((1S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(cyclopropyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(cyclopropyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(methoxymethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((3-oxomorpholino)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-7-fluoro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(cyclopropyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; and (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide.
[0068] In one embodiment, the compound of formula I is the following compound: [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharma- ceutically acceptable salt thereof.
[0069] In one embodiment, the compound of formula I is the following compound: [ka] [ka] or a pharma- ceutically acceptable salt thereof, wherein L is a divalent linking group: [ka] wherein * 1 is the attachment point to the PBG, * 2 is the attachment point to KBG.
[0070] In one embodiment, the compound of formula I is selected from any one of Example compounds 1-6, as described below, or a pharma- ceutically acceptable salt thereof.
[0071] A suitable or preferred feature of any compound of the invention may also be a suitable feature of any other embodiment.
[0072] Suitable pharma- ceutically acceptable salts of the compounds of the invention are, for example, sufficiently basic acid addition salts of the compounds of the invention, for example, acid addition salts with inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid, formic acid, citric acid or maleic acid. In addition, suitable pharma- ceutically acceptable salts of the compounds of the invention that are sufficiently acidic are alkali metal salts, for example, sodium salts or potassium salts, alkaline earth metal salts, for example, calcium salts or magnesium salts, ammonium salts, or salts with organic bases that provide physiologically acceptable cations, for example, salts with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
[0073] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are called "isomers". Isomers that differ in the arrangement of their atoms in space are called "stereoisomers". Stereoisomers that are not mirror images of one another are called "diastereomers" and non-superimposable mirror images of one another are called "enantiomers". When a compound has an asymmetric center, for example, the asymmetric center is bonded to four different groups, a pair of enantiomers is possible. Enantiomers can be characterized by the absolute configuration of their asymmetric center and are described by the R- and S-sequence rules of Cahn and Prelog or by the way the molecule rotates the plane of polarized light and are designated as dextrorotatory or levorotatory (i.e., (+) or (-) isomers, respectively). Chiral compounds can exist as either individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture".
[0074] The compounds of the present invention typically have one or more asymmetric centers, and therefore such compounds can be produced as individual (R)- or (S)-stereoisomers, or as mixtures thereof. Unless otherwise specified, descriptions or references to specific compounds in the specification and claims are intended to include the individual enantiomers, diastereoisomers, and mixtures thereof, otherwise their racemates. Methods for determining stereochemistry and separating stereoisomers are well known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 2001), for example, by synthesis from optically active starting materials or by resolution of racemates. Some of the compounds of the present invention may have geometric isomeric centers (E- and Z-isomers). It should be understood that the present invention encompasses all optical, diastereoisomers, and geometric isomers, and mixtures thereof, that have Nrf2 activation activity.
[0075] The present invention also includes compounds of the invention as defined herein that contain one or more isotopic substitutions. For example, H is 1 H, 2 H(D) and 3 H(T), and C can be in any isotopic form, such as 12 C. 13 C and 14 C, and O may be in any isotopic form, such as 16 O and 18 It may be in any isotopic form, such as O.
[0076] It should also be understood that certain compounds of the present invention may exist in unsolvated as well as solvated forms, such as, for example, hydrates, and the present invention should be understood to encompass all such solvated forms that have Nrf2 activation activity.
[0077] It is also to be understood that certain compounds of the invention may exhibit polymorphism, and the invention encompasses all such forms, which possess Nrf2 activating activity.
[0078] The compounds of the present invention may exist in many different tautomeric forms, and reference to the compounds of the present invention encompasses all such forms.For the avoidance of doubt, when a compound can exist in one of several tautomeric forms and only one form is specifically described or shown, all other forms are also encompassed by the compounds of the present invention.Examples of tautomeric forms include keto, enol and enolate forms, such as the following tautomeric pairs: keto / enol, imine / enamine, amide / iminoalcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol and nitro / acinitro.
[0079] Compounds of the invention containing an amine function may form N-oxides. Reference herein to a compound of formula I containing an amine function also encompasses N-oxides. When a compound contains several amine functions, one or more nitrogen atoms may be oxidized to form N-oxides. Specific examples of N-oxides are the N-oxides of tertiary amines or the nitrogen atoms of nitrogen-containing heterocycles. N-oxides may be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid). For example, see Advanced Organic Chemistry, by Jerry March, 4 th Edition, Wiley Interscience, pages. More specifically, N-oxides can be prepared by the procedure of LW Deady (Syn. Comm. 1977, 7, 509-514), in which an amine compound is reacted with m-chloroperbenzoic acid (MCPBA) in an inert solvent, such as dichloromethane.
[0080] The compounds of the present invention may be administered in the form of prodrugs that break down in the human or animal body to release the compounds of the present invention. Prodrugs may be used to change the physical properties and / or pharmacokinetic properties of the compounds of the present invention. Prodrugs can be formed when the compounds of the present invention contain a suitable group or substituent to which a property-modifying group can be attached. Examples of prodrugs include in vivo cleavable ester derivatives that can be formed at a carboxy or hydroxy group in the compounds of the present invention, and in vivo cleavable amide derivatives that can be formed at a carboxy or amino group in the compounds of the present invention.
[0081] The present invention therefore includes these compounds of formula I as defined above when they are made available by organic synthesis and when they are made available in the human or animal body after cleavage of their prodrugs. The present invention therefore includes these compounds of formula I produced by means of organic synthesis as well as such compounds produced in the human or animal body by metabolism of precursor compounds, i.e. the compounds of formula I may be synthetically produced compounds or metabolically produced compounds.
[0082] Suitable pharma- ceutically acceptable prodrugs of the compounds of formula I are those that, based on sound medical judgment, are suitable for administration to the human or animal body without undesirable pharmacological activity or undue toxicity.
[0083] For various forms of prodrugs, see, for example, the following literature: a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985); b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985); c)A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H.Bundgaard,Chapter 5 “Design and Application of Pro-drugs”, by H.Bundgaard p.113-191(1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992); e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N.Kakeya,et al.,Chem.Pharm.Bull.,32,692(1984); g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, ACSSymposium Series, Volume 14; and h) Described in E. Roche (editor), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987.
[0084] Suitable pharma- ceutically acceptable prodrugs of compounds of formula I having a carboxy group are, for example, in vivo cleavable esters thereof. In vivo cleavable esters of compounds of formula I containing a carboxy group are pharma- ceutically acceptable esters that are cleaved, for example, in the human or animal body, to produce the parent acid. Suitable pharma- ceutically acceptable esters for carboxy include C 1-6 Alkyl esters, such as methyl, ethyl and tert-butyl, 1-6 Alkoxymethyl esters, such as methoxymethyl esters, C 1-6 Alkanoyloxymethyl esters, such as pivaloyloxymethyl esters, 3-phthalidyl esters, etc., C 3-8 Cycloalkylcarbonyloxy-C 1-6Alkyl esters, such as cyclopentylcarbonyloxymethyl and 1-cyclohexylcarbonyloxyethyl esters, 2-oxo-1,3-dioxolenylmethyl esters, such as 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters, and C 1-6 Alkoxycarbonyloxy-C 1-6 Alkyl esters include, for example, methoxycarbonyloxymethyl and 1-methoxycarbonyloxyethyl esters.
[0085] Suitable pharma- ceutically acceptable prodrugs of the compounds of formula I with hydroxyl groups are, for example, in vivo cleavable esters or ethers thereof. The in vivo cleavable esters or ethers of the compounds of formula I containing hydroxyl groups are, for example, pharma- ceutically acceptable esters or ethers that are cleaved in the human or animal body to produce the original hydroxyl compound. Suitable pharma-ceutically acceptable ester-forming groups for hydroxyl groups include inorganic esters, for example, phosphate esters (such as phosphoramidocyclic esters), and the like. Further suitable pharma-ceutically acceptable ester-forming groups for hydroxyl groups include C 1-10 Alkanoyl groups, such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and substituted phenylacetyl groups, 1-10 Alkoxycarbonyl groups, such as ethoxycarbonyl groups, N,N-(C 1-6 ) 2 carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups are aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-(C 1-4Suitable pharma- ceutical-acceptable ether forming groups for a hydroxy group include α-acyloxyalkyl groups, such as acetoxymethyl and pivaloyloxymethyl.
[0086] Suitable pharma- ceutically acceptable prodrugs of compounds of formula I having a carboxy group are, for example, in vivo cleavable amides thereof, for example amides formed with amines, such as ammonia, C 1-4 Alkylamines, such as methylamine (C 1-4 alkyl)2amines, such as dimethylamine, N-ethyl-N-methylamine or diethylamine, 1-4 Alkoxy-C 2-4 Alkylamines, such as 2-methoxyethylamine, phenyl-C 1-4 Alkylamines, such as benzylamine, and amino acids, such as glycine, or esters thereof.
[0087] Suitable pharma- ceutically acceptable prodrugs of compounds of formula I that have an amino group are, for example, in vivo cleavable amide derivatives thereof. Suitable pharma- ceutically acceptable amides from an amino group include, for example, C 1-10 Included are amides formed with alkanoyl groups such as acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups are aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl, and 4-(C 1-4 and alkyl)piperazin-1-ylmethyl.
[0088] The in vivo effects of the compounds of formula I may be exerted in part by one or more metabolites formed in the human or animal body following administration of the compounds of formula I. As described above, the in vivo effects of the compounds of formula I may also be exerted by metabolism of precursor compounds (prodrugs).
[0089] It should also be understood that the compounds of formula I may also be covalently attached (at any suitable position) to other groups, such as solubilizing moieties (e.g., PEG polymers), moieties that allow them to be attached to solid supports (e.g., biotin-containing moieties, etc.), and targeting ligands (e.g., antibodies or antibody fragments, etc.).
[0090] synthesis In the descriptions of the synthetic methods described below, and in the synthetic methods referenced, used to prepare starting materials, it should be understood that all proposed reaction conditions, such as choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and work-up procedures, can be selected by one skilled in the art.
[0091] One skilled in the art of organic synthesis understands that the functionality present on various portions of the molecule must be compatible with the reagents and reaction conditions employed.
[0092] Necessary starting materials may be obtained by standard procedures of organic chemistry. The preparation of such starting materials is described in connection with variants of the representative processes below and within the accompanying Examples. Alternatively, necessary starting materials are obtainable by analogous procedures to those illustrated which are within the ordinary skill of an organic chemist.
[0093] It will be appreciated that during the synthesis of the compounds of the invention in the processes defined below, or during the synthesis of particular starting materials, it may be desirable to protect certain substituents to prevent undesired reactions. The skilled chemist will know when such protection is necessary and how to place such protecting groups in the appropriate positions and subsequently remove them.
[0094] For examples of protecting groups, see any of the many general texts on the subject, e.g., “Protecting groups in Organic Synthesis (3 rdSee, "Protective Groups: A Brief History of Protective Groups," Ed., John Wiley & Sons, NY (1999) by T. Greene & P. Wuts. The protecting groups may be removed by any convenient method described in the literature or known to the skilled chemist to be suitable for the removal of the protecting group in question, such method being selected so as to effect removal of the protecting group with minimal interference to groups present in other parts of the molecule.
[0095] Thus, if the reactants contain groups such as amino, carboxy or hydroxy groups, it may be desirable to protect these groups in some of the reactions mentioned herein.
[0096] For example, suitable protecting groups for amino or alkylamino are, for example, acyl groups, such as acetyl groups, alkanoyl groups, such as alkoxycarbonyl groups, such as methoxycarbonyl groups, ethoxycarbonyl groups or tert-butoxycarbonyl groups, arylmethoxycarbonyl groups, such as benzyloxycarbonyl groups, or aroyl groups, such as benzoyl groups. The deprotection conditions for the above protecting groups necessarily vary according to the choice of protecting group. Thus, for example, acyl groups, such as alkanoyl or alkoxycarbonyl groups, or aroyl groups, can be removed by hydrolysis using a suitable base, such as an alkali metal hydroxide, for example lithium hydroxide or sodium hydroxide. Alternatively, acyl groups such as tert-butoxycarbonyl groups may be removed, for example, by treatment with a suitable acid, such as hydrochloric acid, sulfuric acid or phosphoric acid or trifluoroacetic acid, and arylmethoxycarbonyl groups, such as benzyloxycarbonyl groups, may be removed, for example, by hydrogenation over a catalyst such as palladium on carbon or by treatment with a Lewis acid, for example BF3.OEt2. A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
[0097] Those skilled in the art will recognize that the compounds of the present invention can be prepared in a variety of ways in a known manner. Compounds of formula I can be prepared by empirical methods or similar methods according to the methods provided below. The described routes are only some illustrative of the methods that can be used to synthesize compounds of formula I, and those skilled in the art will understand that the order of reaction steps is not limited to the order described. It will also be understood that the assignment of nucleophiles and electrophiles is not limited to the assignment described herein, and in some cases it may be appropriate for the assignment to be reversed. A different approach to synthetic chemistry strategies is described in “Organic Synthesis: The Disconnection Approach”, 2 nd This is described in the above edition, S. Warren and P. Wyatt (2008).
[0098] The synthesis of exemplary KEAP1 binding groups (KBG) of the present invention are described in WO2020 / 084300 and WO2021 / 214472.
[0099] The synthesis of BRD4 ligands coupled to various linkers is described in doi.org / 10.1038 / s41598-020-72491-9 and doi.org / 10.1021 / jacs.1c04841.
[0100] General method A [ka] In a typical synthetic procedure, the phthalimide, when used as a protecting group, is removed using a typical reagent (e.g., hydrazine) and the amine is reacted with an appropriate reagent to give the desired substituent NR 4 R 5 In the third step, the Boc protecting group (CO2) is then attached, typically by treatment with HCl. t Removes Bu. 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )R 10The group may be introduced in a fourth step from a suitably substituted and protected bis-acid derivative, ideally one of the acid groups is activated for reaction with the amine of the tetrahydroisoquinoline (THIQ) scaffold and the other acid group is suitably protected, for example as a benzyl or dimethoxybenzyl ester, or by ring opening of a suitable cyclic anhydride, or by reaction with an acid chloride. A typical amide coupling reagent such as HATU is used to achieve acid activation. The fifth step is the attachment of the required ether via conventional methods such as alkylation with an alkyl halide or activated alcohol (e.g. mesylate, triflate), or Mitsunobu reaction using reagents such as DBAD or DEAD and a suitable phosphine. The required ether may be the linker-POI, or a suitable ether with the required functionality, or a protecting group to attach the linker-POI in an additional step. In the final step, the protecting group is removed from the carboxylic acid by a suitable method, for example hydrolysis, hydrogenolysis, strong acids such as HCl or TFA, or Lewis acids such as BBr3.
[0101] General method B [ka] In a further exemplary procedure, the order of steps can be changed compared to general method A. The first and second steps are carried out as described in general method A. The third step is the attachment of the required ether via conventional methods such as alkylation with alkyl halides or activated alcohols (e.g. mesylates, triflates), or Mitsunobu reaction using reagents such as DBAD or DEAD and a suitable phosphine. The required ether can be a linker-POI, or a suitable ether with the required functional group, or a protecting group for the attachment of a linker-POI in a subsequent step. The Boc protecting group is then typically removed by treatment with HCl. L 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9)R 10 The group may be introduced from an appropriately substituted and protected bis-acid derivative as described in general method A. In a final step the protecting group is removed from the carboxylic acid by an appropriate method such as, for example, hydrolysis, hydrogenolysis, strong acids such as HCl or TFA, or Lewis acids such as BBr3.
[0102] General method C [ka] In a further exemplary procedure, the order of steps can be changed compared to general methods A and B. In a first step, the required ether is attached, again via conventional methods, as described above in general methods A and B. The phthalimide protecting group is removed in a second step and the amine is reacted with a suitable reagent to give the desired substituent NR 4 R 5 In the fifth step, the Boc protecting group is subsequently removed, and then L 1 C(R 6 )(R 7 )L 2 C(R 8 )(R 9 )R 10 A group may be introduced. The final step involves removal of the carboxylic acid protecting group as described in the general method above.
[0103] General method D [ka] In a further exemplary procedure, general method A can be modified to incorporate functional groups bearing protecting groups that can be reacted to form a covalent bond within the linker. Steps 1-4 are carried out as described in general method A. In the fifth step, the group X-PG is introduced, where PG is a protecting group, e.g., a heterocycle bearing BOC, or a phthalimide protecting group. In the sixth step, the protecting group (PG) can be deprotected using an appropriate method, and in the seventh step, a reactive functional group, e.g., an amine or alcohol, can be further reacted to attach the required linker and PBG. The final step involves the removal of the carboxylic acid protecting group, as described in the general method above.
[0104] R 3 THIQ scaffolds in which is chloro may be made following the route outlined below. [ka] Scheme 1: a) SOCl2, EtOAc; b) 2-(3-methoxyphenyl)ethan-1-amine, Et3N, DCM; c) NCS, DMF; d) P2O5, MeCN; e) Benzene ruthenium(II) chloride dimer, (1S,2S)-(+)-Np-tosyl-1,2-diphenylethylene-diamine, Et3N, HCO2H, MeCN; f) HCl, THF; g) BBr3, DCM; h) Boc2O, DCM.
[0105] In the above general method, the amide group (R 8 =C(O)NR 8a R 8b ) to the corresponding acid group (R 8 =COH) using an amide coupling reaction and reagents well known in the art, such as HATU and 1,1′-carbonyldiimidazole (CDI).
[0106] General method for PBG-L-KBG (R 1 (Installation) PBG-linker (L) is R of KBG 1Compounds of the invention that are attached to a group may be prepared from suitable intermediates that are prepared using the following schemes, where X is any suitable linker chain as described herein.
[0107] [ka] Scheme 2: a) EDCI, HOAt, NMM, b) TFA Coupling of the PBG ligand (exemplified here with the JQ-1 ligand - a BRD4 binder) with a suitably protected amino acid linker followed by suitable deprotection provides the R 1 A PBG-linker-COOH compound is obtained which can be linked to a group.
[0108] [ka] Scheme 3: a) HATU, DIPEA, DMF Alternatively, PBG ligands (exemplified here with the JQ-1 ligand - a BRD4 binder) can be coupled to XY compounds (X being any suitable linker chain as defined herein and Y being a suitable functional group such as an alcohol) via a suitable method to form KBG R 1 This gives a PBG-Linker-Y compound that can be directly linked to a group. X can be an amine to provide an amide-linked compound, or an alcohol to provide an ester-linked compound. Examples of transformations to attach these compounds to KBG include, but are not limited to, ether formation with alkyl halides or activated alcohols (e.g., mesylates, triflates), or Mitsunobu reaction with reagents such as DBAD or DEAD and a suitable phosphine, or ester formation with a suitable alcohol.
[0109] [ka] Scheme 4: a) HATU, DIPEA, DMF In Scheme 4, a functionalized PBG-linker compound (exemplified here as a carboxylic acid) is coupled to R via subsequent amide formation using typical amide coupling conditions, for example, an amide coupling reagent such as HATU. 1 The aryl group may be linked to a substituted aminoethyltriazole group (exemplified here using a substituted aminoethyltriazole).
[0110] [ka] Scheme 5: a) PPh3, DEAD, THF Alternatively, the PBG-Linker-Y compound (exemplified here with a JQ-1 ligand bearing a pendant alcohol group - a BRD4 binder) can be coupled to the KBG R via a suitable method such as ether formation with an alkyl halide or activated alcohol (e.g., mesylate, triflate), or Mitsunobu reaction using reagents such as DBAD or DEAD and a suitable phosphine (exemplified in Scheme 5), or ester formation with an alcohol. 1 It can be linked directly to the group.
[0111] [ka] Scheme 6: a) Cs2CO3, DMF, tert-butyl (2-bromoethyl)carbamate; b) TFA / DCM; c) HOAt, EDCI; d) acid deprotection; e) HOAt, EDCI. The PBG-Linker-COOH compound may be modified to attach an aminoethyl group via subsequent amide formation or using other well-known methods, R 1 It may contain a suitable heterocycle (eg, a pyridine ring as illustrated in Scheme 6 above) to which it can be linked.
[0112] General method for PBG-L-KBG (-NR 4 R 5 (Installation) PBG-linker (L) is KBG-NR 4 R 5Compounds of the invention that are attached to a group may be prepared from suitable intermediates as shown in Scheme 7. [ka] Scheme 7: a) toluene, heating; b) Cs2CO3, DMF, (9H-fluoren-9-yl)methyl(2-bromoethyl)carbamate; c) piperidine; d) HOAt, EDCI; e) acid deprotection; f) HOAt, EDCI.
[0113] General method for PBG-L-KBG (-L 1 -C(R 6 )(R 7 )-L 2 -C(R 8 )(R 9 )(R 10 ) Installation The PBG-linker (L) is a group -L 1 -C(R 6 )(R 7 )-L 2 -C(R 8 )(R 9 )(R 10 Compounds of the invention attached to ) may be prepared from suitable intermediates prepared using the following schemes. [ka] Scheme 8: a) BH3.DMS, NaOH, H2O2; b) Cs2CO3, DMF, (9H-fluoren-9-yl)methyl(2-bromoethyl)carbamate followed by piperidine, DMF; c) HOAt, EDCI; d) acid deprotection; e) HOAt, EDCI; f) TFA / DCM
[0114] Pharmaceutical Compositions The compounds of the present invention will usually, but not necessarily, be formulated into a pharmaceutical composition before being administered to a patient. Thus, in yet another aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of formula I as defined above, or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable excipients.
[0115] The pharmaceutical composition of the present invention can be prepared and packaged in a bulk form from which a safe and effective amount of the compound of the present invention can be extracted, and then provided to the patient using a powder or syrup, etc. Alternatively, the pharmaceutical composition of the present invention can be prepared and packaged in a single dosage form, with each physically separate unit containing a safe and effective amount of the compound of the present invention. When prepared in a single dosage form, the pharmaceutical composition of the present invention typically contains 1 mg to 1000 mg.
[0116] The compositions of the present invention may be in a form suitable for oral use (e.g., tablets, capsules, caplets, pills, troches, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets, and cachets), topical use (e.g., creams, ointments, lotions, solutions, pastes, sprays, foams, and gels), transdermal administration via a transdermal patch, administration by inhalation (e.g., dry powders, aerosols, suspensions and solutions), administration by insufflation (e.g., fine powder), or parenteral administration (e.g., as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal, or intramuscular administration, or as a suppository for rectal administration).
[0117] In a convenient embodiment, the pharmaceutical composition of the present invention is in a form suitable for parenteral administration, such as intravenous or intraperitoneal administration. The solution or suspension used for parenteral administration may contain one or more of the following excipients: a sterile diluent (e.g., water, saline, oil, glycerin, propylene glycol, polyethylene glycol or other pharma- ceutically acceptable solvent); a buffer (e.g., an isotonicity agent such as acetate, citrate, phosphate or sodium chloride or dextrose); a chelating agent (e.g., EDTA); an antibacterial agent (e.g., methylparaben or benzyl alcohol); or an antioxidant (e.g., ascorbic acid or sodium bisulfite). In a convenient embodiment, the pharmaceutical composition of the present invention is in a form suitable for intravenous or intraperitoneal administration and contains phosphate buffered saline or saline. Conveniently, the parenteral composition is enclosed in an ampoule, vial or syringe made of glass or plastic.
[0118] As used herein, "pharmaceutical acceptable excipient" means a material, composition, or vehicle that is pharmaceutical acceptable for providing a shape or consistency to a pharmaceutical composition. Each excipient must be compatible with the other components of the pharmaceutical composition when mixed together to avoid interactions that may substantially reduce the efficacy of the compound of the present invention when administered to a patient, or that may result in a pharmaceutical composition that is pharmaceutical unacceptable. Furthermore, each excipient must be of sufficiently high purity to be pharmaceutical acceptable.
[0119] Suitable pharmaceutically acceptable excipients will vary depending on the particular dosage form selected. Furthermore, suitable pharmaceutically acceptable excipients may be selected for a particular function that they may serve in the composition. For example, certain pharmaceutically acceptable excipients may be selected for their ability to facilitate the manufacture of homogenous dosage forms. Certain pharmaceutically acceptable excipients may be selected for their ability to facilitate the manufacture of stable dosage forms. Certain pharmaceutically acceptable excipients may be selected for their ability to facilitate the transport or transportation of the compound(s) of the present invention from one organ or body part to another organ or body part after administration to a patient. Certain pharmaceutically acceptable excipients may be selected for their ability to enhance patient compliance.
[0120] Suitable pharma- ceutically acceptable excipients include the following types of excipients: diluents, fillers, binders, disintegrants, lubricants, flow agents, granulating agents, coating agents, wetting agents, solvents, cosolvents, suspending agents, emulsifiers, sweeteners, flavors, flavor masking agents, colorants, anticaking agents, humectants, chelating agents, plasticizers, thickeners, antioxidants, preservatives, stabilizers, surfactants, and buffers. Those skilled in the art will appreciate that a particular pharma-ceutically acceptable excipient may perform more than one function, and may perform alternative functions, depending on the amount of the excipient present in the formulation and the other ingredients present in the formulation.
[0121] Those skilled in the art have the knowledge and skill to enable them to select suitable pharma- ceutically acceptable excipients in appropriate amounts for use in the present invention. In addition, there are numerous resources available to those skilled in the art that describe pharma- ceutical acceptable excipients and can assist in selecting suitable pharma- ceutical acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).
[0122] The pharmaceutical compositions of the present invention are prepared using techniques and methods well known to those skilled in the art. Some of the methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).
[0123] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending on the host treated and the particular route of administration. For example, a formulation intended for oral administration to humans will usually contain, for example, 0.5 mg to 0.5 g of active agent (more suitably 0.5 to 100 mg, e.g., 1 to 30 mg), compounded with an appropriate and convenient amount of excipient, which may vary from about 5 to about 98% by weight of the total composition.
[0124] The therapeutic or prophylactic dose of a compound of formula I will naturally vary according to the nature and severity of the pathology, the age and sex of the animal or patient, and the route of administration, in accordance with well-known principles of medicine.
[0125] When the compounds of the present invention are used for therapeutic or prophylactic purposes, they will usually be administered in a daily dose ranging, for example, from 0.1 mg / kg to 75 mg / kg of body weight, to be taken in divided doses if necessary. In general, lower doses will be administered when parenteral routes are used. Thus, for example, for intravenous or intraperitoneal administration, doses ranging, for example, from 0.1 mg / kg to 30 mg / kg of body weight will usually be used. Similarly, for administration by inhalation, doses ranging, for example, from 0.05 mg / kg to 25 mg / kg of body weight will be used. Oral administration, particularly in tablet form, may also be suitable. Typically, a single dosage form will contain about 0.5 mg to 0.5 g of the compound of the present invention.
[0126] Route of administration The compounds of the invention, or pharmaceutical compositions containing the active compounds, may be administered to a subject by any convenient route of administration, whether systemically / peripherally or locally (i.e., to the site of desired activity).
[0127] Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (e.g., by patches, plasters, etc.); transmucosal (e.g., by patches, plasters, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy, e.g., via aerosol, e.g., via the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, e.g., by subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal injection; e.g., by implantation of a depot or reservoir subcutaneously or intramuscularly.
[0128] In a preferred embodiment, the compounds of the invention as defined herein, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, are administered orally, intravenously, subcutaneously, or intramuscularly.
[0129] Therapeutic Uses and Applications The compounds of the present invention are degradation inducers of certain proteins that can be degraded through KEAP1-CUL3 ligase. As a result, the compounds of the present invention are potentially useful therapeutic agents for the treatment of cancer (solid and hematological cancers) and autoimmune diseases.
[0130] Thus, in one aspect, the present invention relates to a compound of formula I as defined herein, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in therapy.
[0131] In another aspect, the present invention relates to a compound of formula I as defined herein, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a disease or disorder resulting from the degradation of a protein of interest.
[0132] In one aspect, the present invention relates to a method for treating a disease or disorder resulting from the degradation of a protein of interest, said method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I as defined herein, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined herein.
[0133] In one aspect, the present invention provides a compound of formula I as defined herein, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in degrading a protein susceptible to degradation by KEAP ligase.
[0134] Proteins that are susceptible to degradation by KEAP ligase include: i) Bromodomain and extra-terminal (BET) family proteins (such as BRD3, BRD4, or BRD9); ii) androgen receptor; iii) estrogen receptor; iv) BCL-XL; v) IRAK4; vi) STAT3; vii) BTK; viii) TRK; or ix) FAK may be mentioned.
[0135] Suitably, the protein susceptible to degradation by KEAP ligase is a bromodomain and extra-terminal (BET) family protein (such as BRD3, BRD4 or BRD9), or FAK. Suitably, the protein susceptible to degradation by KEAP ligase is BRD4.
[0136] In one aspect, the invention provides a method for degrading a protein susceptible to degradation in vivo by KEAP ligase, the method comprising administering a therapeutically effective amount of a compound of formula I, or a pharma- ceutically acceptable salt thereof.
[0137] In one aspect, the present invention provides a compound of formula I as defined herein, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in degrading a protein susceptible to degradation by KEAP ligase, said use comprising contacting a cell with an effective amount of a compound of formula I as defined herein, or a pharma- ceutically acceptable salt thereof.
[0138] In one aspect, the present invention provides a method for degrading a protein susceptible to degradation in vivo by KEAP ligase, said method comprising contacting a cell with an effective amount of a compound of formula I, as defined herein, or a pharma- ceutically acceptable salt thereof.
[0139] In one aspect, the invention relates to a compound of formula I as defined herein, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of cancer or an autoimmune disease.
[0140] In one aspect, the present invention relates to a method for treating cancer or an autoimmune disease, said method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of formula I as defined herein, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined herein.
[0141] The cancer to be treated may be a solid tumor (such as breast cancer, intestinal cancer, colon cancer, lung cancer, liver cancer, bladder cancer, cervical cancer, hepatocellular carcinoma, squamous cell carcinoma, melanoma, glioma, head and neck cancer, sarcoma, pancreatic cancer or prostate cancer), or a hematological cancer (such as leukemia, acute myeloid leukemia, acute lymphocytic leukemia, juvenile myelomonocytic leukemia, multiple myeloma, lymphoma, B-cell malignancies (such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia), or diffuse large B-cell lymphoma). Examples of specific cancers that may be treated using the compounds of formula I and their pharmaceutically acceptable salts include, but are not limited to, any one of prostate cancer, breast cancer, B-cell malignancies, sarcoma, acute myeloid leukemia, multiple myeloma or lymphoma.
[0142] Examples of autoimmune diseases or disorders include rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, autoimmune hemolytic anemia, multiple sclerosis, type 1 diabetes mellitus, Goodpasture's syndrome, Hashimoto's thyroiditis, Guillain-Barre syndrome, immune thrombocytopenic purpura, atherosclerosis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, ankylosing spondylitis, seronegative spondyloarthropathy, autoimmune thyroiditis, Sjogren's syndrome, Hughes' syndrome, psoriasis, psoriatic arthritis, myasthenia gravis, thrombocytopenic purpura, Addison's disease, primary biliary cirrhosis, diffuse scleroderma, polymyositis, dermatomyositis, autoimmune hepatitis, autoimmune sclerosing cholangitis, localized scleroderma, autoimmune uveitis, acquired hemophilia, pernicious anemia, pemphigus, pemphigoid, and vitiligo.
[0143] In one aspect, the invention provides a method for degrading a protein susceptible to degradation in vitro by KEAP ligase, the method comprising administering a therapeutically effective amount of a compound of formula I, or a pharma- ceutically acceptable salt thereof.
[0144] In one aspect, the present invention provides a method for degrading a protein susceptible to degradation in vitro by KEAP ligase, said method comprising contacting a cell with an effective amount of a compound of formula I, as defined herein, or a pharma- ceutically acceptable salt thereof. EXAMPLES
[0145] General Procedure Methods for preparing the compounds of the present invention are illustrated in the following examples. Starting materials are made according to procedures known in the art or as illustrated herein, or are commercially available. All commercially available reagents were used without further purification. If no reaction temperature is included, the reactions were carried out at ambient temperature, which is usually 18-27°C.
[0146] 1 The compounds described in this invention were characterized by H NMR spectroscopy, and the spectra were recorded on a 400 MHz Bruker instrument. If the temperature was not included, the spectra were recorded at ambient temperature. Chemical shift values were expressed in parts per million (ppm). When the NMR spectra are complex due to the presence of interconverting isomers, approximate partial integrals of the signals are reported, or only the characterization of the major isomer is reported. For the multiplicity of the NMR signals, the following abbreviations are used: s = singlet, b = broad line, t = triplet, q = quartet, m = multiplet, d = doublet.
[0147] analyticalLCMS The compounds described in this invention are characterized by LCMS data to determine retention time and molecular weight using the methods listed in the table below. If the molecular weight of the compounds of this invention is outside the detection limit (typically >1200 Da), the LCMS data of the main detected peak is reported (highest % peak area detected by UV).
[0148] Method 1: Acquity UPLC H-Class (PDA, QDa and ELS). Column: Kinetex C18 (5 μm, 50 × 4.6 mm). Conditions: 0.1% formic acid in water [eluent A], MeCN (containing 0.1% formic acid) [eluent B] Flow rate 1.5 mL / min. Gradient: 5-95% B 0.25-1.5 min, hold at 95% B 1.5-2.25 min. Column temperature 40 °C.
[0149] Method 2: Acquity UPLC H-Class (PDA, QDa and ELS). Column: Kinetex Evo C18 (5 μm, 50 × 4.6 mm). Conditions: 10 mM ammonium bicarbonate in water [eluent A], MeCN [eluent B], flow rate 1.5 mL / min. Gradient: 5-60% B 0.25-1.5 min, hold at 60% B 1.5-2.25 min. Column temperature 40 °C.
[0150] Method 3: Acquity UPLC + Waters DAD + Waters SQD2, single quadrupole UPLC-MS. Column: Acquity UPLC HSS C18 (1.8 μm, 100 × 2.1 mm). Conditions: 0.1% formic acid in water [eluent A], MeCN (containing 0.1% (v / v) formic acid) [eluent B], flow rate 0.4 mL / min. Gradient: 5-95% B 0.4-6.0 min, hold at 95% B 6.0-6.8 min. Column temperature 40 °C.
[0151] Method 4: Acquity UPLC + Waters DAD + Waters SQD2, single quadrupole UPLC-MS. Column: Acquity UPLC BEH C18 (1.7 μm, 100 × 2.1 mm). Conditions: 10 mM ammonium bicarbonate in water [eluent A], MeCN [eluent B], flow rate 0.4 mL / min. Gradient: 5-95% B 0.4-6.0 min, hold at 95% B 6.0-6.8 min. Column temperature 40 °C. [Table 1]
[0152] Intermediates Intermediate 1: 2,4-Dimethoxybenzyl (1S,2R)-2-((S)-5-chloro-8-hydroxy-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] Intermediate 1 is described in WO2020 / 084300 (Intermediate 37).
[0153] Intermediate 2: tert-Butyl-(S)(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)glycinate [ka] (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetic acid (1.0 g, 2.49 mmol; CAS: 202592-23-2), tert-butyl 2-aminoacetate hydrochloride (0.63 g, 3.74 mmol; CAS: 202592-23-2) in DMSO (8.3 mL). To a stirred solution of 1-hydroxy-7-azabenzotriazole (0.51 g, 3.74 mmol; CAS: 39968-33-7), 1-hydroxy-7-azabenzotriazole (0.51 g, 3.74 mmol; CAS: 27532-96-3), 1-hydroxy-7-azabenzotriazole (0.51 g, 3.74 mmol; CAS: 39968-33-7), and EDC hydrochloride (0.72 g, 3.74 mmol) was added 4-methylmorpholine (1.1 mL, 9.98 mmol; CAS: 109-02-4) and the reaction mixture was stirred for 18 h at room temperature. Purification by preparative HPLC (C18 120 g, 20-80% MeCN in water (10 mM ammonium bicarbonate)) afforded the title compound (1.08 g, 80%). LCMS (Method 1): 1.70 min, 514.0 [M+H] + .
[0154] Intermediate 3: (S)-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetyl)glycine [ka] To a stirred solution of intermediate 2 (1.08 g, 2.09 mmol) in DCM (4 mL) was added TFA (2.0 mL, 26.0 mmol) and the reaction mixture was stirred for 2 h at room temperature. Further TFA (2.0 mL, 26.0 mmol) was added and the mixture was stirred for a further 2 h and then concentrated in vacuo. The mixture was diluted with DCM and water, passed through a phase separator and the organics concentrated in vacuo. Purification by preparative HPLC (C18 120 g, 20-80% MeCN in water (10 mM ammonium bicarbonate)) afforded the title compound (0.69 g, 72%). LCMS (Method 1): 1.43 min, 458.0 [M+H] + .
[0155] Intermediate 4: tert-Butyl (S)-3-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)propanoate [ka] (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetic acid (1.0 g, 2.49 mmol; CAS: 202592-23-2), tert-butyl 3-aminopropanoate (0.54 g, 3.74 mmol) in DMSO (8.3 mL). To a stirred solution of 4-methylmorpholine (0.82 mL, 7.48 mmol; CAS: 109-02-4) was added 1-hydroxy-7-azabenzotriazole (0.51 g, 3.74 mmol; CAS: 39968-33-7), 1-hydroxy-7-azabenzotriazole (0.51 g, 3.74 mmol; CAS: 39968-33-7), and EDC hydrochloride (0.72 g, 3.74 mmol), and the reaction mixture was stirred for 18 h at room temperature. Purification by preparative HPLC (C18 120 g, 20-80% MeCN in water (10 mM ammonium bicarbonate)) afforded the title compound (899 mg, 68%). LCMS (Method 1): 1.72 min, 528.0 [M+H] + .
[0156] Intermediate 5: (S)-3-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)propanoic acid [ka] To a stirred solution of intermediate 4 (0.40 g, 0.76 mmol) in DCM (2.5 mL) was added TFA (0.7 mL, 9.4 mmol) and the reaction mixture was stirred for 72 h at room temperature and then concentrated in vacuo. The mixture was diluted with DCM and water, passed through a phase separator and the organics were concentrated in vacuo. Purification by preparative HPLC (C18 120 g, 20-80% MeCN in water (10 mM ammonium bicarbonate)) afforded the title compound (0.26 g, 72%). LCMS (Method 1): 1.44 min, 472.0 [M+H] + .
[0157] Intermediate 6: tert-Butyl (S)-3-(2-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethoxy)propanoate [ka] To a stirred solution of (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetic acid (0.40 g, 1.0 mmol; CAS: 202592-23-2) and tert-butyl 3-(2-aminoethoxy)propanoate (0.19 g, 1.0 mmol; CAS: 1260092-46-3) in DMF (3.3 mL) was added DIPEA (0.35 ml, 2.0 mmol) and HATU (0.42 g, 1.1 mmol; CAS: 148893-10-1) and the reaction mixture was stirred for 18 h at room temperature. The reaction mixture was concentrated in vacuo and purified by preparative HPLC (C18 120 g, 20-80% MeCN in water (10 mM ammonium bicarbonate)) to give the title compound (0.29 g, 51%). LCMS (Method 1): 1.72 min, 572.2 [M+H] + .
[0158] Intermediate 7: (S)-3-(2-(2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)ethoxy)propanoic acid [ka] To a stirred solution of intermediate 6 (290 mg, 0.51 mmol) in DCM (2.5 mL) was added TFA (2.0 mL, 26 mmol) and the reaction mixture was stirred for 18 h at room temperature and then concentrated in vacuo. The mixture was diluted with DCM and water, passed through a phase separator and the organics were concentrated in vacuo. Purification by preparative HPLC (C18 120 g, 20-80% MeCN in water (10 mM ammonium bicarbonate)) afforded the title compound (0.20 g, 76%). LCMS (Method 1): 1.45 min, 516.5 [M+H] + .
[0159] Intermediate 8: tert-Butyl (R)-(2-(2-(3-hydroxypyrrolidin-1-yl)-2-oxoethoxy)-ethyl)carbamate [ka] To a stirred solution of 2-(2-((tert-butoxycarbonyl)amino)ethoxy)acetic acid (1.26 g, 5.74 mmol; CAS: 142929-49-5) and (R)-pyrrolidin-3-ol (0.48 mL, 5.74 mmol; CAS: 2799-21-5) in DCM (19 mL) was added DIPEA (2.0 mL, 11.5 mmol) and HATU (2.40 g, 6.31 mmol) and the reaction mixture was stirred for 18 h at room temperature. The mixture was diluted with DCM and washed with sodium hydroxide (1 M aqueous solution). The combined organics were passed through a phase separator and concentrated in vacuo to give the title compound (1.35 g, 82%) which was used without further purification. LCMS (Method 1): 1.17 min, 289.1 [M+H] + .
[0160] Intermediate 9: (R)-2-(2-aminoethoxy)-1-(3-hydroxypyrrolidin-1-yl)ethan-1-one [ka] To a stirred solution of intermediate 8 (1.25 g, 4.34 mmol) in DCM (9 mL) was added TFA (8.0 mL, 104 mmol) and the reaction mixture was stirred for 24 h at room temperature. The mixture was concentrated in vacuo, diluted with DCM / MeOH (1:1) and purified by SCX cartridge (washed with DCM / MeOH (1:1) and eluted with DCM / methanolic ammonia (1:1; 7N NH3)) to give the title compound (449 mg, 55%), which was used without further purification. LCMS (Method 1): 1.01 min, 189.1 [M+H] + .
[0161] Intermediate 10: 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(2-((2-(2-((R)-3-hydroxypyrrolidin-1-yl)-2-oxoethoxy)ethyl)amino)-2-oxoethyl)acetamide [ka] To a stirred solution of (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetic acid (0.46 g, 1.01 mmol; CAS: 202592-23-2) and intermediate 9 (0.19 g, 1.01 mmol) in DMF (3.4 mL) was added DIPEA (0.35 mL, 2.0 mmol) and HATU (0.42 g, 1.11 mmol) and the reaction mixture was stirred for 18 h at room temperature. The reaction mixture was concentrated in vacuo and purified by preparative HPLC (C18 120 g, 20-80% MeCN (0.1% formic acid) / H2O (0.1% formic acid)) to give the title compound (0.34 g, 38%). LCMS (method 1): 1.33 min, 628.3[M+H] + .
[0162] Intermediate 11: 2-(2-(4-(chloromethyl)-5-methyl-1H-1,2,3-triazol-1-yl)ethyl)isoindoline-1,3-dione [ka] To a stirred solution of 2-[2-[4-(hydroxymethyl)-5-methyl-triazol-1-yl]ethyl]isoindoline-1,3-dione (0.2 g, 0.7 mmol, CAS: 1955526-81-4) and triethylamine (0.15 mL, 1.05 mmol) in DCM (3.5 mL) was added methanesulfonyl chloride solution (0.06 mL, 0.84 mmol, CAS: 124-63-0) and the mixture was stirred for 18 hours at room temperature. To this was added saturated aqueous NaHCO3 and the mixture was extracted with DCM. The combined organics were passed through a phase separator and concentrated in vacuo to give the title compound (0.24 g, 98%) which was used without further purification. LCMS (Method 1): 1.38 min, 305.3 [M+H] + .
[0163] Intermediate 12: 2,4-Dimethoxybenzyl (1S,2R)-2-((S)-5-chloro-8-((1-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] To a stirred solution of intermediate 11 (0.23 g, 0.77 mmol) in DMF (1.0 mL) was added intermediate 1 (0.32 g, 0.51 mmol) and cesium carbonate (0.33 g, 1.02 mmol) and the reaction mixture was stirred at room temperature under nitrogen for 7 days. The mixture was diluted with EtOAc and LiCl (4% aq.) and the aqueous layer was re-extracted with EtOAc. The combined organics were dried over MgSO4, passed through a phase separator and concentrated in vacuo. Purification by flash column chromatography (Biotage Isolera™, 25 g silica column, eluted with 0-50% (3:1 EtOAc:EtOH) in cyclohexane) afforded the title compound (0.33 g, 65%). LCMS (Method 1): 1.86 min, 894.0 [M+H] + .
[0164] Intermediate 13: 2,4-Dimethoxybenzyl (1S,2R)-2-((S)-8-((1-(2-aminoethyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] To a stirred suspension of intermediate 12 (0.33 g, 0.33 mmol) in EtOH (3.3 mL), hydrazine monohydrate (0.06 mL, 0.83 mmol, CAS: 7803-57-8) was added and the reaction mixture was heated to 75° C. and stirred for 4 h. It was cooled to room temperature, diluted with additional EtOH and MeCN, and filtered to remove the phthalic acid hydrazide by-product. The filter cake was washed with additional EtOH and MeCN, and the combined filtrate was concentrated in vacuo to give the title compound (0.25 g (estimated quantitative)), which was used without further purification. LCMS (Method 1): 1.79 min, 763.9 [M+H] + .
[0165] Intermediate 14: 2,4-Dimethoxybenzyl (1S,2R)-2-((S)-5-chloro-8-((1-(2-(2-(2((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)acetamido)ethyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] To a stirred solution of intermediate 3 (0.17 g, 0.36 mmol) and intermediate 13 (0.25 g, 0.33 mmol) in DMF (2.2 mL) was added DIPEA (0.17 mL, 0.99 mmol) followed by HATU (0.15 g, 0.4 mmol) and the mixture was stirred at room temperature for 16 h. Purification by preparative HPLC (C18 120 g, 40-100% MeCN in water (10 mM ammonium bicarbonate)) afforded the title compound (0.18 mg, 47%). LCMS (Method 1): 1.93 min, 1202.5 [M+H] + .
[0166] Intermediate 15: 5-(((tert-butyldiphenylsilyl)oxy)methyl)-4-(chloromethyl)-1-methyl-1H-1,2,3-triazole [ka] To a stirred solution of (5-(((tert-butyldiphenylsilyl)oxy)methyl)-1-methyl-1H-1,2,3-triazol-4-yl)methanol (0.53 g, 1.40 mmol; CAS: 432554-87-5, WO2002042305) and triethylamine (0.29 mL, 2.1 mmol) in DCM (5.6 mL) was added methanesulfonyl chloride (0.13 mL, 1.68 mmol) and the reaction mixture was stirred for 48 h at room temperature. To this was added saturated aqueous NaHCO3 and the mixture was extracted with DCM. The combined organics were passed through a phase separator and concentrated in vacuo to give the title compound (0.63 g (estimated quantitative)) which was used without further purification. LCMS (Method 1): 1.95 min, 400.5 [M+H] + .
[0167] Intermediate 16: 2,4-Dimethoxybenzyl (1S,2R)-2-((S)-8-((5-(((tert-butyldiphenylsilyl)oxy)methyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] To a stirred solution of intermediate 15 (0.63 g, 1.58 mmol) in DMF (6.6 mL) was added intermediate 1 (0.83 mg, 1.32 mmol) and cesium carbonate (1.29 g, 3.96 mmol) and the reaction mixture was stirred under nitrogen at room temperature for 16 h. The mixture was diluted with EtOAc and LiCl (4% aq.) and the aqueous layer was re-extracted with EtOAc. The combined organics were dried over MgSO4, passed through a phase separator and concentrated in vacuo. The title compound (1.22 g, 94%) was obtained and used without further purification. LCMS (Method 1): 2.19 min, 989.2 [M+H] + .
[0168] Intermediate 17: 2,4-Dimethoxybenzyl (1S,2R)-2-((S)-5-chloro-8-((5-(hydroxymethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] To a stirred solution of intermediate 16 (1.22 g, 1.23 mmol) in THF (10 mL) and MeOH (2 mL) was added TBAF (1.23 mL, 1.23 mmol; 1 M in THF) and the reaction mixture was stirred for 72 h at room temperature. The mixture was diluted with water, extracted with EtOAc, and the combined organics were washed with brine, passed through a phase separator, and concentrated in vacuo. Purification by flash column chromatography (40 g silica column, eluting with 0-50% [EtOAc:EtOH=3:1] in cyclohexane) afforded the title compound (0.58 g, 50%). LCMS (Method 2): 1.72 min, 750.4 [M+H] + .
[0169] Intermediate 18: 2,4-Dimethoxybenzyl (1S,2R)-2-((S)-5-chloro-8-((5-(chloromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] To a stirred solution of intermediate 17 (0.25 g, 0.33 mmol) and triethylamine (0.08 mL, 0.6 mmol) in DCM (2.2 mL) was added methanesulfonyl chloride (0.04 mL, 0.5 mmol) and the mixture was stirred at room temperature for 16 h. To this was added saturated aqueous NaHCO3 and the mixture was extracted with DCM. The combined organics were passed through a phase separator and concentrated in vacuo to give the title compound (0.23 g, 91%) which was used without further purification. LCMS (Method 1): 1.83 min, 768.8 [M+H] + .
[0170] Intermediate 19: 2,4-Dimethoxybenzyl (1S,2R)-2-((S)-5-chloro-8-((5-((2-(1,3-dioxoisoindolin-2-yl)ethoxy)methyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] To a stirred solution of 2-(2-hydroxyethyl)isoindoline-1,3-dione (60 mg, 0.31 mmol, CAS: 3891-07-4) in anhydrous DMF (0.8 mL) was added sodium hydride (14 mg, 0.36 mmol; 60% dispersion in mineral oil) and the suspension was stirred for 15 min. To this was added a solution of intermediate 18 (0.18 g, 0.24 mmol) in DMF (0.8 mL) and the reaction mixture was heated to 60° C. for 3.5 h. The reaction was diluted with water and partitioned between DCM and LiCl solution (4% aq.). The aqueous phase was further extracted and the combined organics were passed through a phase separator and concentrated in vacuo. The title compound (0.18 g, 41%) was obtained and used without further purification. LCMS (Method 2): 1.87 min, 923.5 [M+H] + .
[0171] Intermediate 20: 2,4-Dimethoxybenzyl (1S,2R)-2-((S)-8-((5-((2-aminoethoxy)methyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] To a stirred suspension of intermediate 19 (0.18 g, 0.2 mmol) in EtOH (2.0 mL) was added hydrazine monohydrate (0.04 mL, 0.49 mmol) and the resulting mixture was heated to 75° C. and stirred for 16 h. The reaction mixture was cooled to room temperature, diluted with additional EtOH and MeCN, and filtered to remove the phthalic acid hydrazide by-product. The filter cake was washed with additional EtOH and MeCN, and the combined filtrate was concentrated in vacuo to give the title compound (0.19 g, 68%), which was used without further purification. LCMS (Method 2): 1.81 min, 793.5 [M+H] + .
[0172] Intermediate 21: 2,4-Dimethoxybenzyl (1S,2R)-2-((S)-5-chloro-8-((5-((2-(2-(2((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)acetamido)ethoxy)methyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] To a stirred solution of intermediate 3 (0.14 g, 0.3 mmol) and intermediate 20 (0.19 g, 0.23 mmol) in DMF (2.2 mL) was added DIPEA (0.12 mL, 0.7 mmol) and HATU (0.13 g, 0.33 mmol) and the mixture was stirred at room temperature for 18 h. Purification by preparative HPLC (C18 120 g, 40-100% MeCN in water (10 mM ammonium bicarbonate)) afforded the title compound (98 mg, 30%). LCMS (Method 2): 1.85 min, 1082.5 [M-DMB+2H] + .
[0173] Intermediate 22: 2,4-Dimethoxybenzyl (1S,2R)-2-((S)-5-chloro-8-((5-((2-(3-(2((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)propanamido)ethoxy)methyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] To a stirred solution of intermediate 5 (0.13 g, 0.27 mmol) and intermediate 20 (0.14 g, 0.18 mmol) in DMF (2.2 mL) was added DIPEA (0.12 mL, 0.72 mmol) and HATU (0.14 g, 0.38 mmol) and the mixture was stirred at room temperature for 16 h. Purification by preparative HPLC (C18 120 g, 40-100% MeCN in water (10 mM ammonium bicarbonate)) afforded the title compound (69 mg, 31%). LCMS (Method 2): 1.82 min, 1096.5 [M-DMB+2H] + .
[0174] Intermediate 23: 2,4-Dimethoxybenzyl (1S,2R)-2-((S)-5-chloro-8-((5-(14((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-6,13-dioxo-2,9-dioxa-5,12-diazatetradecyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] To a stirred solution of intermediate 7 (0.19 g, 0.37 mmol) and intermediate 20 (0.14 g, 0.18 mmol) in DMF (1.8 mL) was added DIPEA (0.12 mL, 0.72 mmol) and HATU (0.14 g, 0.38 mmol) and the mixture was stirred at room temperature for 16 h. Purification by preparative HPLC (C18 120 g, 40-100% MeCN in water (10 mM ammonium bicarbonate)) afforded the title compound (38 mg, 13%). LCMS (Method 2): 1.82 min, 1140.6 [M-DMB+2H] + .
[0175] Intermediate 24: 2,4-Dimethoxybenzyl (1S,2R)-2((S)-5-chloro-8-(((S)-1-(2-(2-(2-(2((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)acetamido)ethoxy)acetyl)pyrrolidin-3-yl)oxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylate [ka] To a stirred solution of intermediate 10 (0.14 g, 0.22 mmol) and intermediate 1 (0.14 g, 0.22 mmol) in THF (1.5 mL) was added triphenylphosphine (64 mg, 0.25 mmol; CAS: 603-35-0) and DEAD (0.11 mL, 0.25 mmol; 40% in toluene, CAS: 1972-28-7) and the reaction mixture was stirred for 18 h at room temperature. The reaction mixture was heated to 50° C. for 5 h, cooled to room temperature, and additional triphenylphosphine (64 mg, 0.25 mmol; CAS: 603-35-0) and DEAD (0.11 mL, 0.25 mmol; 40% in toluene, CAS: 1972-28-7) were added. The reaction mixture was heated to 60° C. for 16 h, cooled to room temperature, and concentrated in vacuo. Purification by preparative HPLC (C18, 40-100% MeCN in water (10 mM ammonium bicarbonate)) afforded the title compound (27 mg, 2%). LCMS (Method 2): 1.78 min, 1084.4 [M-DMB+2H] + .
[0176] Example 1: (1S,2R)-2-((S)-5-chloro-8-((1-(2-(2-(2((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)acetamido)ethyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid [ka] To a stirred solution of intermediate 14 (0.18 g, 0.15 mmol) and triethylsilane (0.19 mL, 1.2 mmol, CAS: 617-86-7) in DCM (1.5 mL) at room temperature, TFA (0.05 mL, 0.6 mmol) was added and the reaction mixture was stirred for 1 h at room temperature. The mixture was concentrated in vacuo, the residue was diluted with EtOAc (100 mL) and the organics were washed with water. The combined organics were passed through a phase separator, dried (Na2SO4) and concentrated in vacuo. Purification by preparative HPLC (C18 120 g, 20-80% MeCN in water (10 mM ammonium bicarbonate)) afforded the title compound (60 mg, 38%). LCMS (Method 3): 5.02 min, 1052.8 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 12.05-11.52 (bm, 1H), 8.74-8.60 (m, 1H), 8.19-8.04 (m, 1H), 7.52-7.42 (m, 4H), 7.36 (d, 1H), 7.13 (d, 1H), 5.80-5.73 (m, 1H), 5.16-5.06 (m, 2H), 4.52 (t, 1H), 4.34 (t, 2H), 4.03-3.87 (m, 2H), 3.81 (dd, 1H), 3.66-3.44 (m, 4H), 3.43-3.23 (m, 3H), 3.06-2.94 (m, 2H), 2.85-2.76 (m, 1H), 2.75-2.64 (m, 2H), 2.61 (s, 3H), 2.43-2.22 (m, 7H), 2.19 (d, 1H), 2.09 (d, 1H), 1.73-1.47 (m, 6H), 1.45-1.18 (m, 4H), 1.10 (s, 3H), 0.60-0.38 (m, 4H).
[0177] Example 2: (1S,2R)-2-((S)-5-chloro-8-((1-(2-(2-(2((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)acetamido)ethyl)-5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide [ka] To a stirred suspension of HATU (6.5 mg, 0.02 mmol) and DIPEA (0.02 mL, 0.02 mmol) in DMF (0.2 mL) was added Example 1 (15 mg, 0.01 mmol) and methylamine solution (0.02 mL, 0.03 mmol; 2.0 M in THF, CAS: 74-89-5) and the reaction mixture was stirred for 18 h at room temperature. Additional methylamine solution (0.1 mL, 0.2 mmol; 2.0 M in THF, CAS: 74-89-5), DIPEA (0.02 mL, 0.11 mmol), and HATU (40 mg, 0.11 mmol) were added and stirred for 72 h. The reaction mixture was concentrated in vacuo and purified by preparative HPLC (C18 120 g, 20-80% MeCN in water (10 mM ammonium bicarbonate)) to give the title compound (11 mg, 74%). LCMS (Method 3): 4.79 min, 1065.7[M+H] + . 1H NMR (400 MHz, DMSO-d6) δ 8.65 (t, 1H), 8.07 (t, 1H), 7.52-7.43 (m, 4H), 7.37 (d, 1H), 7.29-7.20 (m, 1H), 7.15 (d, 1H), 5.79-5.68 (m, 1H), 5.17-5.05 (m, 2H), 4.52 (t, 1H), 4.34 (t, 2H), 4.01-3.86 (m, 2H), 3.81 (dd, 1H), 3.66-3.45 (m, 4H), 3.43-3.22 (m, 3H), 3.07-2.93 (m, 2H), 2.85-2.65 (m, 3H), 2.62 (s, 3H), 2.43-2.35 (m, 7H), 2.33 (s, 3H), 2.20 (d, 1H), 2.09 (d, 1H), 1.69-1.58 (m, 4H), 1.57-1.43 (m, 3H), 1.42-1.28 (m, 2H), 1.28-1.12 (m, 1H), 1.05 (s, 3H), 0.61-0.36 (m, 4H).
[0178] Example 3: (1S,2R)-2-((S)-5-chloro-8-((5-((2-(2-(2((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)acetamido)ethoxy)methyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid [ka] To a stirred solution of intermediate 21 (97 mg, 0.08 mmol) and triethylsilane (0.2 mL, 1.3 mmol, CAS: 617-86-7) in DCM (0.8 mL) was added TFA (0.05 mL, 0.6 mmol) and the reaction mixture was stirred for 4 h at room temperature. The mixture was concentrated in vacuo and purified by preparative HPLC (C18, 5-60% MeCN in water (10 mM ammonium bicarbonate)). The residue was taken up in MeCN / water (1:1) and lyophilized to give the title compound (41 mg, 45%). LCMS (Method 3): 4.94 min, 1082.7 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 12.14-11.59 (bm, 1H), 8.69-8.49 (bm, 1H), 8.01-7.79 (bm, 1H), 7.51-7.41 (m, 4H), 7.33 (d, 1H), 7.13 (d, 1H), 5.79-5.73 (m, 1H), 5.21 (s, 2H), 4.76-4.65 (m, 2H), 4.52 (t, 1H), 4.05-3.88 (m, 5H), 3.79 (dd, 1H), 3.68-3.53 (m, 2H), 3.53-3.45 (m, 2H), 3.41-3.22 (m, 5H), 3.05-2.93 (m, 2H), 2.86-2.76 (m, 1H), 2.76-2.62 (m, 2H), 2.58 (s, 3H), 2.41 (s, 3H), 2.35-2.22 (m, 1H), 2.18 (d, 1H), 2.10 (d, 1H), 1.72-1.47 (m, 6H), 1.46-1.17 (m, 4H), 1.11 (s, 3H), 0.62-0.37 (m, 4H).
[0179] Example 4: (1S,2R)-2-((S)-5-chloro-8-((5-((2-(3-(2((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)propanamido)ethoxy)methyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid [ka] To a stirred solution of intermediate 22 (69 mg, 0.06 mmol) and triethylsilane (0.14 mL, 0.89 mmol) in DCM (0.8 mL) was added TFA (0.03 mL, 0.44 mmol) and the reaction mixture was stirred at room temperature for 4 h. The mixture was concentrated in vacuo and purified by preparative HPLC (C18, 5-60% MeCN in water (10 mM ammonium bicarbonate)). The residue was taken up in MeCN / water (1:1) and lyophilized to give the title compound (30 mg, 48%). LCMS (Method 3): 4.85 min, 1096.7 [M+H] +. 1H NMR (400 MHz, DMSO-d6) δ 11.95-11.75 (bm, 1H), 8.35-8.13 (bm, 1H), 8.08-7.86 (bm, 1H), 7.51-7.46 (m, 2H), 7.45-7.39 (m, 2H), 7.34 (d, 1H), 7.13 (d, 1H), 5.79-5.73 (m, 1H), 5.25-5.16 (m, 2H), 4.76-4.64 (m, 2H), 4.50 (t, 1H), 4.05-3.87 (m, 5H), 3.64-3.52 (m, 1H), 3.50-3.41 (m, 2H), 3.39-3.13 (m, 7H), 3.03-2.93 (m, 2H), 2.85-2.77 (m, 1H), 2.77-2.61 (m, 2H), 2.59 (s, 3H), 2.41 (s, 3H), 2.35-2.23 (m, 3H), 2.21-2.06 (m, 2H), 1.70-1.47 (m, 6H), 1.45-1.18 (m, 4H), 1.10 (s, 3H), 0.61-0.40 (m, 4H).
[0180] Example 5: (1S,2R)-2-((S)-5-chloro-8-((5-(14((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-6,13-dioxo-2,9-dioxa-5,12-diazatetradecyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid [ka] To a stirred solution of intermediate 23 (38 mg, 0.03 mmol) and triethylsilane (0.08 mL, 0.47 mmol) in DCM (0.5 mL) was added TFA (0.02 mL, 0.24 mmol) and the reaction mixture was stirred at room temperature for 4 h. The mixture was concentrated in vacuo and purified by preparative HPLC (C18, 20-80% MeCN in water (10 mM ammonium bicarbonate)). The residue was taken up in MeCN / water (1:1) and lyophilized to give the title compound (13 mg, 36%). LCMS (Method 4): 4.30 min, 1140.7 [M+H] + . 1 H NMR (400 MHz, DMSO-d6) δ 8.33-8.22 (bm, 1H), 7.51-7.46 (m, 2H), 7.45-7.39 (m, 2H), 7.34 (d, 1H), 7.13 (d, 1H), 5.78-5.72 (m, 1H), 5.24-5.16 (m, 2H), 4.75-4.61 (m, 2H), 4.53-4.48 (m, 1H), 4.04-3.85 (m, 5H), 3.65-3.52 (m, 3H), 3.49-3.12 (m, 11H), 3.03-2.93 (m, 2H), 2.85-2.62 (m, 3H), 2.59 (s, 3H), 2.41 (s, 3H), 2.36-2.25 (m, 3H), 2.18 (d, 1H), 2.10 (d, 1H), 1.69-1.45 (m, 6H), 1.44-1.17 (m, 4H), 1.09 (s, 3H), 0.60-0.40 (m, 4H).
[0181] Example 6: (1S,2R)-2-((S)-5-chloro-8-(((S)-1-(2-(2-(2-(2((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamido)acetamido)ethoxy)acetyl)pyrrolidin-3-yl)oxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid [ka] To a stirred solution of intermediate 24 (27 mg, 0.022 mmol) and triethylsilane (0.06 mL, 0.35 mmol) in DCM (0.2 mL) was added TFA (0.01 mL, 0.17 mmol) and the reaction mixture was stirred at room temperature for 4 h. The mixture was concentrated in vacuo and purified by preparative HPLC (C18, 5-60% MeCN (10 mM ammonium bicarbonate) in water). The residue was taken up in MeCN / water (1:1) and lyophilized to give the title compound (4.4 mg, 12%). LCMS (Method 3): 4.83 min, 1084.5 [M+H] + . 1 1 H NMR (400 MHz, CDCl3) - Complex mixture containing characteristic peaks for the title compound.
[0182] Comparative Example Comparative Example 1: (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(2-(2-(2((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamide)acetamide)ethyl)-1-methylcyclohexane-1-carboxamide [ka] Comparative Example 2: (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(2-(2-(2((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamide)ethoxy)ethyl)-1-methylcyclohexane-1-carboxamide [ka] Comparative Example 3: (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(2-(2-(2-(2((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamide)ethoxy)ethoxy)ethyl)-1-methylcyclohexane-1-carboxamide [ka]
[0183] Biological assays Beas2B NQO1 mRNA cell-based assay NRF2-mediated upregulation of the gene NAD(P)H:quinone receptor oxidoreductase 1 (NQO1) was measured using the following assay: BEAS-2B cells (ATCC CRL-9609) were plated at 20,000 cells / well in 96-well clear plates in 75 μL of cell culture medium and cultured overnight (37°C, 5% CO2). On day 2, 25 μL of compound or control was added to the cells for 24 hours. On day 3, the culture medium was aspirated from the plates and expression analysis was performed directly from the cultured cells without RNA purification using the Cells-to-CT™ 1-Step TaqMan® Kit (Ambion A25603) according to the manufacturer's instructions.
[0184] Briefly, cells were washed with ice-cold PBS and 22.5 μL of DNase / cell lysate at room temperature was added to the cells and incubated at room temperature for 5 min. To stop the reaction, 2.25 μL of stop solution was added to the cell lysate. Samples were diluted 1:5 with nuclease-free water and 2.5 μL was transferred to the PCR plate. Real-time PCR was performed using a C-1000 Thermal Cycler (Bio-Rad) with human β-actin as an internal control. cDNA was amplified with specific primers for NQO1 using 1-step RT-PCR master mix (Ambion Cells-to-CT™ 1-Step TaqMan® Kit A25603). Primer / probe sets used for cDNA amplification were obtained from TaqMan Gene Expression Assays (Applied Biosystems). Relative mRNA levels of the target gene NQO1 were calculated using the comparative C T (ΔΔC T) relative quantification method as described in the Applied Biosystems Chemistry Guide. Data were expressed as the increase in target gene mRNA compared to vehicle (0.1% DMSO) control and EC was calculated by fitting the data to a four-parameter logistic fit using XLfit or XE Runner in ActivityBase. 50 The EC values of the tested compounds were determined. 50 The values are shown in Table 1. [Table 2]
[0185] BRD4 Degradation Assay Protocol Overview MDA-MB-468 cells were routinely cultured in DMEM supplemented with 10% heat-inactivated FBS and 1% penicillin-streptomycin (ThermoFisher Scientific) at 37°C and 5% CO2. Cells were plated in 6-well plates with 4 wells per well. *10^5 cells were seeded and allowed to adhere overnight. Example compounds were dissolved in DMSO to make 10 mM stocks and then serially diluted in DMSO to 200x final concentrations. These were further diluted in culture medium to obtain 20x treatment stocks, which were then added to the cells at 1x final concentration. Cells were then incubated at 37°C, 5% CO2 for 24 or 48 hours, after which the cells were lysed in RIPA buffer supplemented with cOmplete Mini Protease Inhibitor Cocktail and PhosSTOP™ (Roche). Lysates were clarified by centrifugation at 13,000 RPM for 10 minutes, and the protein concentrations of the resulting supernatants were determined by BCA assay (ThermoFisher Scientific) according to the manufacturer's instructions. Lysates were denatured and reduced in NuPAGE LDS sample buffer and sample reducing agent, and 10 μg was loaded onto NuPAGE 2-8% Tris-Acetate Mini Protein Gels (ThermoFisher Scientific). Proteins were transferred to nitrocellulose membranes using a Trans-Blot Turbo Transfer System (Bio-Rad) and then blocked for 1 h in Intercept (TBS) Blocking Buffer (Li-Cor). Membranes were then incubated overnight with BRD4 (ab128874; Abcam) and α-tubulin (T6074; Sigma-Aldrich) antibodies diluted 1:2000 and 1:16,000, respectively, in Tris-buffered saline 0.05% Tween 20 (TBS-T). The next day, the membranes were washed with TBS-T, and then anti-rabbit IRDye 800CW and mouse anti-IRDye 680LT secondary antibodies (LiCor) (diluted 1:10,000 in TBS-T) were added for 1 h. The membranes were then washed with TBS-T and imaged using Image Studio Ver 5.2 software (LiCor) with a LICOR Odyssey Infrared Imaging System.Densitometric analysis was performed in LiCor image studio software and BRD4 signal was normalized to α-tubulin signal. The percentage of BRD4 degradation was calculated as follows: = 100-(signal of interest / signal of control sample) compared to DMSO-treated negative control. * 100). BRD4 degradation by dBET1 was used as a positive control for each plate. Treatment with Example Compounds 1-6 and Comparative Compounds 1-3 yielded percentage data of BRD4 degradation after 24 hours of incubation, as shown in Table 2, and after 48 hours of incubation, as shown in Table 3.
[0186] The Beas2B assay data in Table 1 shows that all compounds tested (Examples 1-6 and Comparative Examples 1-3) were able to bind to Keap1 and activate Nrf2, as measured by an increase in downstream NQO1 mRNA. The BRD4 degradation data in Tables 2 and 3 show that (i) Example 1 degraded the target protein almost completely at ≧0.1 μM, with up to 75% degradation even at a concentration of 0.01 μM; (ii) Examples 1-6 all resulted in dose-responsive degradation of BRD4, with over 60% degradation of the long isoform and over 77% degradation of the short isoform after 48 hours of incubation; and (iii) Comparative Examples 1-3 did not significantly degrade any of the BRD isoforms or did not show dose-responsive target protein degradation. [Table 3] [Table 4]
Claims
1. Formula I: 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, wherein L is a divalent linking group covalently linking KBG to PBG; The PBG is a protein binding group that includes a moiety that has binding affinity for a target protein of interest; The KBG has the structure shown below: 【Chemistry 2】 is a KEAP1 binding group having the formula: R 1 is C 1-4 Alkylene-R 11 , heterocyclyl, and 8-10 membered bicyclic heteroaryl, wherein the heterocyclyl is independently selected from C 1-4 Alkyl, —C(O)—R 12 , S.O. 2 -R 13 , C 1-3 Alkylene-OR 14 and, independently, C. 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH, C 1-3 Optionally substituted by one or more substituents selected from heteroaryl, optionally substituted by one or more substituents selected from alkoxy and cyano; said 8-10 membered bicyclic heteroaryl is independently selected from C 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH and C 1-3 optionally substituted with one or more substituents selected from alkoxy; R 2 is hydrogen, fluoro, chloro and C 1-3 alkyl; R 3 is hydrogen, fluoro, chloro, bromo, C 1-3 Alkoxy, C 1-3 Alkyl, C 1-3 selected from haloalkyl and cyano; R 4 is hydrogen or C 1-4 is alkyl, R 5 is -C(O)-C 1-4 alkyl, -C(O)-heteroaryl or -C(O)-aryl, wherein the heteroaryl and the aryl are C 1-4 Alkyl, halo, hydroxy, C 1-3 Alkoxy, CO 2 R 15 and cyano; or R 4 and R 5 together with the nitrogen atom to which they are attached form a 4-, 5- or 6-membered heterocyclyl ring, said heterocyclyl ring being containing one or more -C(O)- moieties attached to said nitrogen atom; optionally fused to an aryl or heteroaryl ring; C 3-7 optionally spiro-attached to the cycloalkyl group; Independent C 1-4 Alkyl, halo, OH, C 1-3 Alkoxy, C 1-3 Haloalkyl, cyano, NR 16 R 17 , C(O)R 18 , S(O)R 19 and S.O. 2 R 20 optionally substituted with one or more substituents selected from L 1 and L 2 is a bond and -CR 21 R 22 - independently selected from; R 6 and R 7 are independently hydrogen, C 1-4 Alkyl and C 3-7 cycloalkyl; or R 6 and R 7 together with the carbon atom to which they are attached form a 3-, 4-, 5-, or 6-membered cycloalkyl ring; R 8 is C(=O)NR 8a R 8b , -C(=O)R 8c , CO 2 R 23 , C(O)NHSO 2 C 1-3 alkyl, tetrazolyl, 3-trifluoromethyl-1,2,4-triazol-5-yl, and carboxylic acid analogs selected from hydroxamic acids, hydroxamic acid esters, phosphonic acids, phosphinic acids, sulfonic acids, sulfinic acids, sulfonamides, sulfonylureas, acylureas, thiazolidinediones, oxazolidinediones, oxadiazol-5(4H)-ones, thiadiazol-5(4H)-ones, oxathiadiazol-2-oxides, oxadiazole-5(4H)thiones, isoxazoles, tetramic acids, cyclopentane-1,3-dione, and cyclopentane-1,2-dione; R 8a is hydrogen or C 1-6 is alkyl, R 8b is hydrogen, C 1-6 Alkyl or C 3-7 cycloalkyl, 1-6 Alkyl group or the C 3-7 The cycloalkyl group is C 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH, C 1-3 Alkoxy, C 1-3 Haloalkyl, cyano, NR 16 R 17 , C(O)R 18 , S(O)R 19 and S.O. 2 R 20 or R 8a and R 8b together with the nitrogen atom to which they are attached form a 3-, 4-, 5-, 6- or 7-membered heterocyclyl ring, said heterocyclyl ring optionally containing one or more further heteroatoms selected from oxygen, nitrogen and sulfur, and further comprising C 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH, C 1-3 Alkoxy, C 1-3 Haloalkyl, cyano, NR 16 R 17 , C(O)R 18 , S(O)R 19 and S.O. 2 R 20 optionally substituted with one or more substituents independently selected from R 8c is C 1-3 Alkyl or C 1-3 haloalkyl; R 9 is hydrogen, C 1-4 Alkyl, Hydroxy, C 1-3 selected from alkoxy and halo; R 10 is hydrogen and C 1-4 alkyl; or R 9 and R 10 together with the carbon atom to which they are attached form a 3-, 4-, 5-, or 6-membered cycloalkyl ring; or L 2 is a bond, R 7 and R 10 together with the atoms to which they are attached form a 4-, 5-, 6- or 7-membered cycloalkyl or heterocyclyl ring; said heterocyclyl ring contains 1 or 2 heteroatoms independently selected from nitrogen, oxygen, and sulfur; The cycloalkyl ring optionally contains one or two carbon-carbon double bonds, and further contains a C 1-3 Optionally bridged by alkylene groups, or R 9 optionally, a carbon atom of the ring may have a C * C which connects 1-3 is an alkylene group; The cycloalkyl ring and the heterocyclyl ring are 1-4 Alkyl, halo, OH, C 1-3 Alkoxy, C 1-3 optionally substituted with one or more substituents independently selected from haloalkyl and deuterium; R 11 is -C(O)-R 24 , -SO 2 -R 25 , -NR 26 C(O)-R 27 , -NR 28 SO 2 -R 29 , heterocyclyl, aryl and heteroaryl, wherein the heterocyclyl, aryl and heteroaryl groups are selected from 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 Optionally substituted with one or more substituents independently selected from alkoxy, heterocyclyl, and cyano; said heterocyclyl group is 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy, oxo, and cyano; R 12 is C 1-4 Alkyl, C 3-7 Cycloalkyl, OR 31 , N.R. 32 R 33 , aryl and heteroaryl, wherein the aryl and the heteroaryl are selected from C 1-4 Alkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; R 13 is C 1-4 Alkyl, C 3-7 Cycloalkyl, heteroaryl, heterocyclyl and NR 34 R 35 wherein said heteroaryl and said heterocyclyl are selected from 1-4 Alkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; R 17 is hydrogen, C 1-4 Alkyl, C(O)C 1-3 Alkyl and C(O)NR 36 R 37 Selected from: R 18 , R 19 and R 20 is C 1-4 Alkyl, OH, C 1-3 Alkoxy and NR 38 R 39 are independently selected from; R 23 is hydrogen and C 1-4 alkyl; R 24 is C 1-4 Alkyl, NR 40 R 41 and OR 42 Selected from: R 25 is C 1-4 Alkyl and NR 43 R 44 Selected from: R 27 is C 1-4 Alkyl, C 3-7 Cycloalkyl, C 1-3 haloalkyl, heterocyclyl, aryl and heteroaryl, wherein the aryl and the heteroaryl are selected from 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 45 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; R 29 is C 1-4 Alkyl, C 3-7 Cycloalkyl, C 1-3 haloalkyl, aryl and heteroaryl, said aryl and said heteroaryl being selected from 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 46 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; R 30 is hydroxy, C 1-3 Alkoxy, C 3-7 Cycloalkyl, cyano and NR 47 R 48 Selected from: R 40 is hydrogen and C 1-4 alkyl; R 41 is hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl, C 1-3 selected from alkoxy, aryl and heteroaryl; or R 40 and R 41 together with the nitrogen atom to which they are attached form a 4-, 5- or 6-membered heteroaryl or heterocyclyl ring, said heteroaryl and heterocyclyl rings being C 1-4 Alkyl, halo, OH, C 1-3 Alkoxy, C 3-7 optionally substituted with one or more substituents independently selected from cycloalkyl and cyano; R 45 and R 46 is hydroxy, C 1-3 Alkoxy and C 3-7 cycloalkyl; R 14 , R 15 , R 16 , R 21 , R 22 , R 26 , R 28 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 42 , R 43 , R 44 , R 47 and R 48 is hydrogen, C 1-4 Alkyl and C 3-7 cycloalkyl; or a pharma- ceutically acceptable salt thereof.
2. The KBG has the following structural formulas (II) to (VIII): 【Chemistry 3-1】 【Chemistry 3-2】 wherein R 1 ~R 10 , L 1 and L 2 is as defined in claim 1; the cyclohexyl or cyclopentyl ring in formulae (III) to (VIII) is 1-4 Alkyl, halo, OH, C 1-3 Optionally substituted with one or more substituents independently selected from alkoxy and deuterium, and further comprising a C linking two carbon atoms of the ring; 1-3 Optionally bridged by alkylene groups, R 9 optionally, a carbon atom of the ring may have a C * C which connects 1-3 The compound of claim 1 which is an alkylene group.
3. R 8 CO 2 R 23 and R 23 The compound according to any one of claims 1 to 2, wherein is hydrogen.
4. R 9 is hydrogen or C 1-4 The compound according to any one of claims 1 to 3, which is alkyl.
5. R 9 The compound of claim 4 , wherein is methyl.
6. R 1 C 1-4 Alkylene-R 11 The compound according to any one of claims 1 to 5,
7. R 1 CH 2 -R 11 7. The compound of claim 6,
8. R 11 but, (A)-C(O)-R 24 , -NR 26 C(O)-R 27 and heteroaryl, said heteroaryl being selected from C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy, heterocyclyl, and cyano; (B) C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 heteroaryl optionally substituted with one or more substituents independently selected from alkoxy, heterocyclyl, and cyano; (C) Methyl, ethyl, isopropyl, difluoromethyl, trifluoromethyl, chloro, fluoro, cyclopropyl, methoxy, cyano, oxetanyl, CH 2 -R 30 and C 2 H 4 -R 30 or (D) C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 The compound according to any one of claims 1 to 7, which is pyridyl, pyrimidinyl, pyridazinyl, oxazolyl, isoxazolyl, 1,2,3-triazolyl, 1,2,4-oxadiazolyl, benzotriazolyl, benzisoxazolyl, isoxazolopyridinyl, imidazopyridinyl or triazolopyridinyl, each optionally substituted by one or more substituents independently selected from alkoxy, heterocyclyl and cyano.
9. R 11 but, 【Chemistry 4】 is selected from C 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 The compound of any one of claims 1 to 7, optionally substituted with one or more substituents independently selected from alkoxy, heterocyclyl and cyano.
10. R 1 is selected from the following groups: 【Chemistry 5】 wherein: 【Chemistry 6】 indicates the point of attachment of said group to the oxygen atom of the remainder of said compound, and each of said cyclic groups is 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 The compound of any one of claims 1 to 5, optionally substituted with one or more substituents independently selected from alkoxy, heterocyclyl and cyano.
11. R 1 but, (A)-C(O)-R 12 , S.O. 2 -R 13 , heteroaryl and C 1-3 Alkylene-OR 14 and wherein the heteroaryl is a heterocyclyl optionally substituted by one or more substituents independently selected from 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; (B) piperidinyl or pyrrolidinyl, each of which is —C(O)—R 12 , S.O. 2 -R 13 , heteroaryl and C 1-3 Alkylene-OR 14 and wherein the heteroaryl is optionally substituted with one or more substituents independently selected from 1-4 Alkyl, C 3-7 Cycloalkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and cyano; (C)-C(O)-R 12 , S.O. 2 -R 13 , heteroaryl and C 1-3 Alkylene-OR 14 and pyrrolidinyl optionally substituted by one or more substituents independently selected from 1-4 Alkyl or C 3-7 cycloalkyl is optionally substituted; or (D) the following group: 【Chemistry 7】 is selected from one of 【Chemistry 8】 indicates the point of attachment of said group to an oxygen atom of the remainder of said compound, and each said group is -C(O)-R 12 , S.O. 2 -R 13 , heteroaryl and C 1-3 Alkylene-OR 14 and wherein the heteroaryl is optionally substituted with one or more substituents independently selected from 1-4 Alkyl or C 3-7 The compound of any one of claims 1 to 5, wherein the cycloalkyl is optionally substituted.
12. R 2 The compound according to any one of claims 1 to 11, wherein is hydrogen or fluoro.
13. R 3 The compound according to any one of claims 1 to 12, wherein is hydrogen or chloro.
14. R 4 is hydrogen, R 5 But -C(O)-C 1-4 alkyl or -C(O)-aryl, wherein the aryl is 1-4 Alkyl, halo, hydroxy, C 1-3 Alkoxy, CO 2 R 15 14. The compound of any one of claims 1 to 13, optionally substituted with one or more substituents selected from:
15. R 4 and R 5 together with the nitrogen atom to which they are attached, (A) forming a 5- or 6-membered heterocyclyl ring, said heterocyclyl ring containing one or more -C(O)- moieties attached to said nitrogen atom and optionally fused to an aryl ring, or 3-7 Optionally spiro-linked to the cycloalkyl group, and further 1-4 Alkyl, halo, OH, C 1-3 Alkoxy, C 1-3 Haloalkyl, cyano, NR 16 R 17 , C(O)R 18 , S(O)R 19 and S.O. 2 R 20 optionally substituted with one or more substituents independently selected from (B) forming a 5- or 6-membered heterocyclyl ring, said heterocyclyl ring containing a —C(O)— moiety attached to said nitrogen atom and optionally fused to an aryl ring, or 3-7 The cycloalkyl group is optionally spiro-linked, and the heterocyclyl ring is 1-4 optionally substituted with one or more substituents independently selected from alkyl, halo, and OH; or (C) Below: 【Chemistry 9】 and a saturated ring of said heterocyclic moiety is selected from one of 3-7 Optionally spiro-linked to the cycloalkyl group, said heterocyclic moiety being 1-4 The compound of any one of claims 1 to 13, optionally substituted with one or more substituents independently selected from alkyl, halo and OH.
16. R 8a The compound according to any one of claims 1 to 15, wherein is hydrogen.
17. R 8b but, a) Hydrogen, C 1-4 Alkyl or C 3-5 cycloalkyl, 1-4 The alkyl group is halo, OH, C 1-3 Alkoxy, C 3-7 optionally substituted with one or more substituents independently selected from cycloalkyl and cyano; b) C 1-4 Alkyl or C 3-5 cycloalkyl, 1-4 The alkyl group is fluoro, OH, C 1-3 Alkoxy, C 3-7 optionally substituted with one or more substituents independently selected from cycloalkyl and cyano; or The compound according to any one of claims 1 to 16, wherein c) is methyl.
18. The KBG is selected from the group: (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(2-(5-methylisoxazole-3-carboxamido)ethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(2-(benzo[d]oxazole-2-carboxamido)ethoxy)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(5-methylisoxazole-3-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(2-methylthiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-((1-methyl-1H-benzo[d]imidazol-5-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5-bromo-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5-chloro-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5,7-dichloro-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethoxy)-5-bromo-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5-bromo-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-(((S)-1-(2-methylthiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-(((S)-1-(5-methylthiazol-2-yl)pyrrolidin-3-yl)oxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-(((S)-1-(5-methylpyridazin-3-yl)pyrrolidin-3-yl)oxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((4-methyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-methyl-1H-imidazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-methylisoxazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((2-ethyl-2H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-bromo-8-((5-methylthiazol-2-yl)methoxy)-1-((1-oxo-1,3,3a,4,5,6-hexahydro-2H-isoindol-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-methyl-1H-1,2,4-triazol-5-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-1-((1-oxoisoindolin-2-yl)methyl)-8-(pyridazin-3-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-(cyclopropylmethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-(imidazo[1,2-a]pyridin-7-ylmethoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-methyl-1H-benzo[d]imidazol-5-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-(methyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-(isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-methyl-1,3,4-oxadiazol-2-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((7-methoxy-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1-((1oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-methyl-1H-1,2,4-triazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-isopropyl-1H-imidazol-2-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((4-ethyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-cyano-1-ethyl-1H-imidazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-1-((1-oxoisoindolin-2-yl)methyl)-8-((5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-bromo-8-(1-(1-methyl-1H-1,2,3-triazol-4-yl)ethoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-bromo-8-(1-(1-isopropyl-1H-1,2,3-triazol-4-yl)ethoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-methylisoxazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethoxy)-5-chloro-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((1-oxoisoindolin-2-yl)methyl)-8-((1-(2,2,2-trifluoroethyl)-1H-imidazol-2-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-(2,2-difluoroethyl)-1H-imidazol-2-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-ethyl-1H-pyrazol-3-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-imidazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-fluoro-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methyl-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-cyano-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-5-methoxy-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-5-(trifluoromethyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-1-((2-oxopyrrolidin-1-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethoxy)-5-bromo-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-methylthiazol-2-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((5-isopropyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-bromo-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(benzo[d]isothiazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyridin-2-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-methylisothiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-(isothiazol-3-ylmethoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-bromo-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((S)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyridin-3-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-ethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (R)-4-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3-methyl-4-oxobutanoic acid; 1-(((S)-2-((1R,2S)-2-(2H-tetrazol-5-yl)cyclohexane-1-carbonyl)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)pyrrolidin-2-one; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-isopropyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((4-methyl-1H-pyrazol-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyrimidin-5-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclopentane-1-carboxylic acid; (1R,2S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyridazin-3-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((3-methyl-3H-imidazo[4,5-b]pyridin-6-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-(imidazo[1,2-a]pyrimidin-2-ylmethoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-(isoxazolo[5,4-b]pyridin-3-ylmethoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((3-methylisoxazolo[5,4-b]pyridin-6-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; 3-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)bicyclo[2.2.1]heptane-2-carboxylic acid; 3-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)tetrahydrofuran-2-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-indazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((3-methyl-3H-imidazo[4,5-b]pyridin-5-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; 2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4,4-difluorocyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4,5-dimethyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1R,2S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-fluorocyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((S)-3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((S)-3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((S)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-ethylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-ethylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-ethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-ethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-isopropyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4,5-dimethylisoxazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-chloro-5-methylisoxazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-methylisoxazol-5-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(methoxymethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(2-methoxyethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(cyclopropyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-(((S)-3-methyl-2-oxopyrrolidin-1-yl)methyl)-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-(((R)-3-methyl-2-oxopyrrolidin-1-yl)methyl)-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2S)-2-((S)-5-chloro-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-cyclopropyl-5-(difluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-(difluoromethyl)pyrimidin-5-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5,5-dimethyl-4,5-dihydroisoxazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-methylisoxazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-((4,5,6,7-tetrahydrobenzo[d]isoxazol-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((2,5-bis(difluoromethyl)-2H-1,2,3-triazol-4-yl)methoxy)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; 2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)tetrahydro-2H-pyran-3-carboxylic acid; (R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)bicyclo[2.2.2]octane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid-4,4-d2 acid; (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-(2-methoxyethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5,6-dihydro-4H-pyrrolo[1,2-c][1,2,3]triazol-3-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-2-oxo-1,2-dihydropyridin-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; 1-(((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-2-((1R,2S)-2-methyl-2-(2H-tetrazol-5-yl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)pyrrolidin-2-one; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((4,4-dimethyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-methyl-4-(trifluoromethyl)isoxazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-(2,2,2-trifluoroethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-(difluoromethyl)-5-methylisoxazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(cyclopropyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(methoxymethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(methoxymethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(cyclopropyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-chloro-8-((7-fluoro-2,7a-dihydrobenzo[d]isoxazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((6,7-difluorobenzo[d]isoxazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-methylisoxazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((3-methyl-1,2,4-oxadiazol-5-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2S)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4-(trifluoromethyl)pyrimidin-5-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-cyclopropyl-5-(difluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-(2-(dimethylamino)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-1-methyl-2-((S)-5-methyl-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-methyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazin-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4-cyclopropyl-5-methyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-fluoro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4,5-dimethyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5,6-dihydro-4H-pyrrolo[1,2-c][1,2,3]triazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-cyclopropyl-4-methyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-imidazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-(((S)-1-(methylsulfonyl)pyrrolidin-3-yl)oxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((s)-8-(((s)-1-acetylpyrrolidin-3-yl)oxy)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((s)-5-chloro-8-((6,7-dihydro-4H-[1,2,3]triazolo[5,1-c][1,4]oxazin-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-1-methyl-2-((S)-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-bromo-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((s)-5-chloro-8-((5-(difluoromethyl)-1-(oxetan-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-8-((1,5-bis(difluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-5-chloro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-2-methyl-5-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((s)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((s)-2-methyl-5-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-1-((3-oxomorpholino)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxylic acid; (1S,2R)-2((S)-5-bromo-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(oxetan-3-yl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((3-oxomorpholino)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,6R)-6-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohex-3-ene-1-carboxylic acid; 5-(((S)-2-((1R,2S)-2-(1H-tetrazol-5-yl)cyclohexane-1-carbonyl)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-5-azaspiro[2.4]heptan-6-one; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)thiazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-methylthiazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((2-methyl-2H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1R,3S,4R,6S)-4-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-3-methylbicyclo[4.1.0]heptane-3-carboxylic acid; (1S,3S,4R,6R)-4-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-3-methylbicyclo[4.1.0]heptane-3-carboxylic acid; (1S,2R)-2-((1S)-5-chloro-8-((6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-7-yl)oxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R,4S,5R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid-4,5-d2 acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-2-oxo-1,2-dihydropyridin-3-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxo-4-(trifluoromethyl)pyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-6-oxo-1,6-dihydropyridin-2-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((1S)-5-chloro-8-((1-methyl-1,4,5,6-tetrahydrocyclopenta[d][1,2,3]triazol-5-yl)oxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4,4-difluoro-1-methylcyclohexane-1-carboxylic acid; (1S,2R,4S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4-fluoro-1-methylcyclohexane-1-carboxylic acid; (1S,2R,4R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid-4-d acid; (1S,2R,4S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4-hydroxy-1-methylcyclohexane-1-carboxylic acid; (1S,2R,5S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-5-hydroxy-1-methylcyclohexane-1-carboxylic acid; (1S,2R,5R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-5-hydroxy-1-methylcyclohexane-1-carboxylic acid; (1S,2R,4R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-4-hydroxy-1-methylcyclohexane-1-carboxylic acid; (2S,3R)-3-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)tetrahydro-2H-pyran-2-carboxylic acid; (1R,2R,6S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-6-hydroxy-1-methylcyclohexane-1-carboxylic acid; (1R,2R,6R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-6-hydroxy-1-methylcyclohexane-1-carboxylic acid; (1S,2S,3R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-3-hydroxy-1-methylcyclohexane-1-carboxylic acid; (1S,2S,3S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-3-hydroxy-1-methylcyclohexane-1-carboxylic acid; 5-(((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-2-((1R,2S)-2-methyl-2-(1H-tetrazol-5-yl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)-5-azaspiro[2.4]heptan-6-one; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((3-oxomorpholino)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclopentane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-8-((4,5-dimethyl-4H-1,2,4-triazol-3-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-7-fluoro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-5-chloro-7-fluoro-8-((5-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxylic acid; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(4-(methylamino)-4-oxobutoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(ethylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)-5-methylisoxazole-3-carboxamide; (1S,2R)-2-((S)-1-(cyclopropanecarboxamidomethyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-((1H-pyrazol-5-yl)methoxy)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-(acetamidomethyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-N-methyl-2-((S)-1-((2-oxooxazolidin-3-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; 4-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)butanoic acid; (R)-1-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylpiperidine-2-carboxamide; (S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylpyrrolidine-1-carboxamide; 1-(((S)-5-chloro-2-((S)-1-(2,2-difluoroacetyl)piperidine-2-carbonyl)-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl)pyrrolidin-2-one; (S)-6((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methyl-5-azaspiro[2.4]heptane-5-carboxamide; (1R,2S)-2-((R)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(4-oxo-4-(pyrrolidin-1-yl)butoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; 5-cyclopropyl-N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)isoxazole-3-carboxamide; N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)-4,5-dimethylisoxazole-3-carboxamide; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; N-(2-(((S)-2-((1R,2S)-2-(cyclopropylcarbamoyl)cyclohexane-1-carbonyl)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)-5-methylisoxazole-3-carboxamide; N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(3-hydroxyazetidine-1-carbonyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)-5-methylisoxazole-3-carboxamide; N-(2-(((S)-2-((1R,2S)-2-(cyclobutylcarbamoyl)cyclohexane-1-carbonyl)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)-5-methylisoxazole-3-carboxamide; 5-cyclopropyl-N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)isoxazole-3-carboxamide; N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)benzo[d]oxazole-2-carboxamide; N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)benzo[d]isoxazole-3-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(2-((5-methylisoxazole)-4-sulfonamido)ethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(pyrimidine-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-nicotinoylpyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-((5-methylisoxazol-4-yl)sulfonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; N-(2-(((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-2-((1R,2S)-2-(methylcarbamoyl)cyclohexane-1-carbonyl)-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)ethyl)thiazole-2-carboxamide; (1S,2R)-2-((S)-8-(((S)-1-(cyclopropanecarbonyl)pyrrolidin-3-yl)oxy)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(5-methylisoxazole-3-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(oxazol-5-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(2-methylthiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-(((S)-1-(2,4-dimethylthiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(2-methylthiazole-4-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (R)-4-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)-N,3-dimethyl-4oxobutanamide; (1S,2R)-N-methyl-2-((S)-1-((2-oxopyrrolidin-1-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(pyrazin-2-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (S)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylpiperidine-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-propylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(2-methoxyethyl)cyclohexane-1-carboxamide; (1S,2R)-N-(2,2-difluoroethyl)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(2,2,2-trifluoroethyl)cyclohexane-1-carboxamide; (1S,2R)-N-(cyanomethyl)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; (1S,2R)-N-(2,2-difluoro-3-hydroxypropyl)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(2-hydroxyethyl)cyclohexane-1-carboxamide; 1-((S)-1-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)-1-oxopropan-2-yl)-3-methylurea; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5-chloro-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; 5-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-5-oxopentanamide; 4-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-3,4-dihydroisoquinolin-2(1H)-yl)-N-methyl-4-oxobutanamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-ethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(3-hydroxypropyl)cyclohexane-1-carboxamide; (1S,2R)-N-methyl-2-((S)-1-(propionamidomethyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; (1S,2R)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-((1-methyl-1H-pyrazol-4-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-(((S)-1-acetylpyrrolidin-3-yl)oxy)-5-bromo-1-((1,3-dioxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; Methyl (S)-2-((S)-1-((1,3-dioxoisoindolin-2-yl)methyl)-8-(((S)-1-(thiazole-5-carbonyl)pyrrolidin-3-yl)oxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)pyrrolidine-1-carboxylate; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-ethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)cyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-bromo-8-((5-isopropyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-bromo-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-isopropyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (2R,3R)-4-((S)-5-chloro-8-((5-isopropyl-1,2,4-oxadiazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-3,4-dihydroisoquinolin-2(1H)-yl)-N,2,3-trimethyl-4-oxobutanamide; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyridin-3-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyridazin-3-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyrazin-2-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyridin-2-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-8-(pyrimidin-5-ylmethoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; 2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclopentane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-(2-(1-methyl-1H-1,2,3-triazol-4-yl)ethoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((3-methyl-3H-imidazo[4,5-b]pyridin-6-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-(isoxazolo[5,4-b]pyridin-3-ylmethoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((3-methylisoxazolo[5,4-b]pyridin-6-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-(imidazo[1,2-a]pyrimidin-2-ylmethoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-([1,2,4]triazolo[4,3-a]pyridin-3-ylmethoxy)-5-chloro-1-((1-oxoisoindolin-2-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-(2,2-difluoro-3-hydroxypropyl)cyclohexane-1-carboxamide; (S)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylpiperidine-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((3-methyl-3H-imidazo[4,5-b]pyridin-5-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-indazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; 3-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methyltetrahydrofuran-2-carboxamide; (1S,2R)-2-((S)-8-(benzo[d]isoxazol-3-ylmethoxy)-5-chloro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclopentane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((4,5-dimethyl-4H-1,2,4-triazol-3-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide; (S)-3-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylmorpholine-4-carboxamide; (S)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylpyrrolidine-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (S)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylpiperidine-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclopentane-1-carboxamide; (1S,2R)-2-((1S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclopentane-1-carboxamide; (1S,2R)-2-((1S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((3-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-5-(trifluoromethyl)-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(cyclopropyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(cyclopropyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(methoxymethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((3-oxomorpholino)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-7-fluoro-8-((1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-8-((4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridin-3-yl)methoxy)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((1,5-dimethyl-1H-1,2,3-triazol-4-yl)methoxy)-7-fluoro-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-1-methylcyclohexane-1-carboxamide; (1S,2R)-2-((S)-5-chloro-8-((5-(cyclopropyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-(((R)-4-methyl-2-oxopyrrolidin-1-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N,1-dimethylcyclohexane-1-carboxamide; and 2. The compound of claim 1, selected from one of (1S,2R)-2-((S)-5-chloro-8-((5-(difluoromethyl)-1-methyl-1H-1,2,3-triazol-4-yl)methoxy)-1-((6-oxo-5-azaspiro[2.4]heptan-5-yl)methyl)-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)-N-methylcyclohexane-1-carboxamide.
19. L is a covalent bond or a divalent, saturated or unsaturated, straight or branched hydrocarbon chain containing 1 to 50 carbon atoms; the 0 to 6 alkylene units of L are independently -Cy-, -O-, -N(R), -S-, -OC(O)-, -C(O)O-, -S(O)-, -S(O) 2 -, -N(R)S(O) 2 -, -S(O) 2 N(R)-, -N(R)C(O)-, -C(O)N(R)-, -OC(O)N(R)-, 【Chemistry 10】 is replaced by; Each -Cy- is i) phenylenyl, ii) 8-10 membered bicyclic arylenyls; iii) 4- to 7-membered saturated or partially unsaturated carbocyclenyl; iv) 4- to 7-membered saturated or partially unsaturated spiro carbocyclenyls; v) 8-10 membered bicyclic, saturated or partially unsaturated carbocyclylenyl; vi) 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1 to 2 heteroatoms independently selected from nitrogen, oxygen and sulfur; vii) 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; viii) an 8-10 membered bicyclic, saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, sulfur or oxygen; ix) 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur; and x) an independently optionally substituted divalent ring selected from 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each n is independently 1 to 10; Each R is independently hydrogen, or C 1-6 19. The compound of any one of claims 1 to 18, optionally substituted with a group selected from alkyl, phenyl, a 4- to 7-membered saturated or partially unsaturated heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen and sulfur, and a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
20. L is a divalent, saturated or unsaturated, straight or branched hydrocarbon chain containing 1 to 20 carbon atoms; the 0 to 6 alkylene units of L are independently -O-, -N(R), -S-, -OC(O)-, -C(O)O-, -S(O)-, -S(O) 2 -, -N(R)S(O) 2 -, -S(O) 2 N(R)-, -N(R)C(O)-, -C(O)N(R)-, -OC(O)N(R)-, 4- to 7-membered saturated or partially unsaturated heterocyclylenyl having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur; 【Chemistry 11】 is replaced by; Each n is independently 1 to 10; each R is independently hydrogen or C 1-6 20. The compound of claim 19, which is alkyl.
21. L is a divalent, saturated linear hydrocarbon chain containing 5 to 15 carbon atoms; 2 to 6 alkylene units of L are independently -O-, -N(R), -S-, -OC(O)-, -C(O)O-, -S(O)-, -S(O) 2 -, -N(R)S(O) 2 -, -S(O) 2 N(R)-, -N(R)C(O)-, -C(O)N(R)-, -OC(O)N(R)-, 5- to 7-membered saturated heterocyclylenyl having 1 to 2 heteroatoms independently selected from nitrogen, oxygen and sulfur; 【Chemistry 12】 Replaced by; Each n is independently 1 to 5; each R is independently hydrogen or C 1-3 21. The compound of claim 20, which is alkyl.
22. L is the following group: 【Chemistry 13】 wherein: * is a point of attachment to said KBG or said PBG; m is 0 to 4; each p is independently 1 to 4; each R is independently hydrogen or C. 1-3 20. The compound of claim 19, which is alkyl.
23. L is -R on the KBG 1 group, -N(R 4 ) (R 5 ) group, or -L 1 C(R 6 ) (R 7 ) L 2 C(R 8 ) (R 9 ) (R 10 23. The compound of any one of claims 1 to 22, wherein the compound is covalently bonded to any one of the following groups:
24. L is the -R 1 The compound of any one of claims 1 to 22, which is covalently attached to a group.
25. R 1 but, 【Chemistry 14】 is a group selected from 【Chemistry 15】 indicates the point of attachment of said group to the oxygen atom of the remaining said KBG; each said group is 1-4 Alkyl, C 1-3 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Alkylene-R 30 , Halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy, heterocyclyl, and cyano; * 25. The compound of claim 24, wherein indicates the point of attachment of the linking group L.
26. L is the group -N(R 4 ) (R 5 ) covalently bonded to R 4 Or R 5 24. The compound of claim 23, wherein:
27. L is the group -N(R 4 ) (R 5 ) and is covalently bonded to -N(R 4 ) (R 5 ) has the following structure: 【Chemistry 16】 is selected from one of 【Chemistry 17】 indicates the point of attachment of said group to the remainder of said KBG; each said group is 1-4 optionally substituted with one or more substituents independently selected from alkyl, halo, and OH; * 24. The compound of claim 23, wherein indicates the point of attachment of the linking group L.
28. L is the group -L on the KBG 1 C(R 6 ) (R 7 ) L 2 C(R 8 ) (R 9 ) (R 10 ) covalently bonded to -L 1 C(R 6 ) (R 7 ) L 2 C(R 8 ) (R 9 ) (R 10 ) has the following structure: 【Chemistry 18】 is selected from one of 【Chemistry 19】 indicates the point of attachment of said group to the remainder of said KBG; each said group is 1-4 Alkyl, halo, OH, C 1-3 optionally substituted with one or more substituents independently selected from alkoxy and deuterium; * 24. The compound of claim 23, wherein indicates the point of attachment of the linking group L.
29. The PBG is a protein binding group comprising a moiety that has binding affinity for a target protein of interest; the target protein of interest is: (i) Bromodomain and extra-terminal (BET) family proteins (such as BRD3, BRD4, or BRD9); (ii) the androgen receptor; (iii) estrogen receptor; (iv) BCL-XL; (v) IRAK4; (vi) STAT3; (vii) BTK; or (viii) A compound according to any one of claims 1 to 28, which is a TRK.
30. The target protein of interest is BRD4, and optionally the moiety having binding affinity is 【Chemistry 20】 where: * 30. The compound of claim 29, wherein indicates the point of attachment of the linking group L.
31. A pharmaceutical composition comprising a compound of formula I according to any one of claims 1 to 30, or a pharma- ceutically acceptable salt thereof, and one or more pharma- ceutically acceptable excipients.
32. A compound of formula I as defined in any one of claims 1 to 30, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined in claim 31, for use in therapy.
33. A compound of formula I as defined in any one of claims 1 to 30, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined in claim 31, for use in the treatment of cancer or an autoimmune disease.
34. A compound of formula I as defined in any one of claims 1 to 30, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined in claim 31, for use in the degradation of a protein susceptible to degradation by KEAP ligase.
35. 1. A method for degrading a protein susceptible to degradation in vitro by KEAP ligase, comprising: a. administering an effective amount of a compound of formula I, as defined in any one of claims 1 to 30, or a pharma- ceutically acceptable salt thereof; or b. The method comprising contacting a cell with an effective amount of a compound of formula I as defined in any one of claims 1 to 30, or a pharma- ceutically acceptable salt thereof.
36. A method for treating cancer or an autoimmune disease, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I as defined in any one of claims 1 to 30, or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition as defined in claim 31.
Citation Information
Patent Citations
Therapeutic compounds
WO2020084300A1
Redox flow battery for storing electrical energy in underground storage means, and use thereof
WO2020108788A2
Methods and materials for modulating NRF2 pathway
WO2021067799A1
